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Chapter-1
Introduction
1. INTRODUCTION
ULCER 1:
A peptic ulcer is a sore in the lining of stomach or duodenum. The duodenum is the first
part of small intestine. Peptic ulcers are found in the stomach are called as gastric ulcers, in the
duodenum are called duodenal ulcers.
Figure no.1: Peptic ulcer occur in the stomach
Causes of peptic ulcer 2, 3, 4:
 Peptic ulcers are caused by acid and pepsin (an enzyme) produced in the stomach. Patients
who develop ulcers often produce greater amounts of acid than people without ulcers. Also,
the ulcer patient may not have strong enough natural defenses in the stomach or intestinal
wall to resist the effect of acid and pepsin.
 Doctors do not yet know all the reasons for too much acid production, but many believe the
key to healing an ulcer is to control the amount of acid produced.
 Bacteria called Helicobacter pylori, or H. pylori.
 Nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin and ibuprofen
 Symptoms of peptic ulcer 2, 3,4:
 Duodenal Ulcer symptoms:
1. Pain that awakens patients from sleep.
2. Burning sensation in the upper abdomen.
3. Pain in the back, lower abdomen or chest area may occasionally occur.
4. Pain that occurs when the stomach is empty (about two hours after a meal or during the
night).
 Gastric Ulcer symptoms:
1. Gastric ulcer pain may be less severe than duodenal ulcer pain and is noticeably higher in the
abdomen.
2. Eating may increase pain rather than relieve pain.
3. Pain is described as aching, nagging, cramping or dull.
4. Other symptoms may include nausea, vomiting and weight loss.
 Some ulcers may produce no symptoms at all. However, occasional painless bleeding,
anemia (low blood count), or the passage of black tarry stool may be the first sign of peptic
ulcer disease.
Diagnosis of peptic ulcer 4:
 Diagnosis can often be made from the patient’s symptoms.
 X-ray:- The ulcer can be diagnosed by an indentation in the stomach or duodenal wall by
using barium.
 Endoscopy – this is a more accurate method of diagnosing ulcer disease in stomach and
duodenum with a lighted flexible tube. Gastric ulcers, unlike duodenal ulcers, can
occasionally be cancerous. Therefore, endoscopy and biopsy of the gastric ulcer are
commonly used for the diagnosis and follow-up of ulcers.
ANTIULCER DRUGS 5, 6:
The drugs which are used in the treatment of ulcer are called as antiulcer drugs.
Classification of antiulcer drug:
1. Reduction of gastric acid secretion:
a) H2 Antihistamines: cimetidine, ranitidine, famotidine, roxatidine.
b) Proton pump inhibitor: omeprazole, lansoprazole, pantoprazole, rabeprazole, esomeprazole.
c) Anticholinergic: pirenzepine, propantheline, oxyphenonium.
d) Prostaglandine analogue: misoprostol.
2. Neutralization of gastric acid (antacid).
a) Systemic: sodium biocabonate, sodium Citrate.
b) Nonsystemic: magnesium hydroxide, magnesium Trisilicate, aluminium hydroxide gel,
magaldrate, calcium carbonate.
3. Ulcer protectives: sucralfate, colloidal bismuth subcitrate.
4. Anti-H. Pylori drugs: amoxicillin, clarithromycin, metronidazole, tinidazole, tetracycline.
PROTON-PUMP INHIBITORS 5, 6:
The proton-pump inhibitors inhibit gastric acid by blocking the H+/K+-adenosine
triphosphatase enzyme system (the proton pump) of the gastric parietal cell. Examples are
omeprazole, esomeprazole, lansoprazole, pantoprazole and rabeprazole. omeprazole inhibits
cytochrome P450 and lansoprazole is a weak inducer of cytochrome P450. The indications for
proton-pump inhibitors include the following:
 Benign duodenal and gastric ulcers.
 NSAID-associated peptic ulcer and gastro-duodenal erosions.
 In combination with antibacterial drugs to eradicate H. pylori.
 Zollinger–Ellison syndrome.
 Gastric acid reduction during general anaesthesia, gastro-esophageal reflux disease (GORD).
 Stricturing and erosive oesophagitis where they are the treatment of choice.
Side effect of antiulcer drugs 5, 6:
Antacids suppress the absorption of other anti-ulcer drugs, tetracyclines, iron pills, etc.
affect their efficacy. These two types of drugs should therefore be taken separately, with an
interval of one or two hours. Antacids of different formulas may produce mild laxative effect or
result in constipation.
INTRODUCTION OF NOVEL DRUG DELIVERY SYSTEM 8, 9:
Incorporating an existing medicine into a novel drug delivery system (NDDS) can
significantly improve its performance in terms of efficacy, safety and improved patient
compliance. In the form of a NDDS, an existing drug molecule can get new life, thereby
increasing its market value and competitiveness.
Multiparticulate dosage forms are pharmaceutical formulations in which the active
substance is present as a number of small independent subunits with diameter of 0.05-2.00 mm.
To deliver the recommended total dose, these subunits are filled into a capsule or compressed
into a tablet. They provide many advantages over single-unit systems because of their small size.
Multiparticulates are less dependent on gastric emptying, resulting in less inter and intra-subject
variability in gastrointestinal transit time. They are also better distributed and less likely to cause
local irritation.
Recently much emphasis is being laid on the development of multiparticulate dosage
forms in preference to single unit systems because of their potential benefits such as increased
bioavailability, reduced risk of systemic toxicity, reduced risk of local irritation and predictable
gastric emptying.
Types of Multipaticulate drug delivery system 8, 9, 10:
In order to get MPDDS, drug is distributed in small particles (0.05 to 0.2 mm) and then
film coated to get desired drug release characteristics.
Different types of Multipaticulate drug delivery system are as follows:-
Drug Crystals
Drug Crystals of appropriate size and shape can be coated directly with a modified
release film coating.
Irregular Granules
Granules used in preparation of tablets, can be film coated, irregular shape and variation
in particle size make it difficult to achieve uniform coating thickness around each particle.
Spheronized Granules (pellets)
Sphere-shaped particles simplify the coating process. The production of spheroidal
particles (pellets) is achieved by extruding the powdered mass, then cutting into small cylindrical
particles and finally spheronizing these particles to spherical shape.
Drug-loaded Non-pareils (pellets)
Spherical particles about 1mm in diameter consisting primarily of sucrose and starch
called “non-pareils” which are available in the market. Following techniques can be used to get
drug loaded non pareils.
 A powder-dosing technique involving alternate dosing of powder (containing drug substance)
and binder liquid onto the surface of the non-pareils until the required dose of the drug has
been loaded.
 Spray application of drug, either suspended or dissolved in a suitable solvent (usually water)
containing a polymer (such as hydroxyl propyl methyl cellulose or polyvinyl pyrrolidone) as
a binder onto the surface of the non-pareils.
Mini tablets
Many of the other types of multiparticulates described suffer from two potential batch
wise drawbacks, namely:
 Variation in particle size distribution
 Variation in particle shape and surface roughness.
Such variability can results in variable coating thickness and thus product performance. This
Problem can be overcome by using mini compressed tablets (size range of 1-2mm) produced
using modification of traditional tabletting processes.
Melt-Spray-Congeal Microspheres
Spherical, smooth, 50- to 300-μm particles, typically with embedded API, can be
produced by a continuous spinning-disk process
PELLETS 8, 9,10,11,12:
Pellets are agglomerates of fine powders or granules of bulk drugs and excipients. They
consist of small, free-flowing, spherical or semi-spherical solid units, typically from about 0.5
mm to 1.5 mm, and are intended usually for oral administration. Implants of small, sterile
cylinders formed by compression from medicated masses are also defined as pellets in pharmacy.
Pellets can be formulated by many ways, the compaction and drug-layering techniques are the
most widely used.
Regardless of which manufacturing process is used, pellets have to meet the following
Requirements:
(1) They should be near spherical and have a smooth surface; both considered important
characteristics for subsequent film coating.
(2) The particle size range should be as narrow as possible. The optimum size of pellets for
pharmaceutical application is considered to be between 600 and 1000 μm.
(3) The pellets should contain high percentage of the active ingredient, maintaining the size of
the final dosage form within reasonable limits.
Pellets offer a great flexibility in pharmaceutical solid dosage form design and
development. They flow freely and pack easily without significant difficulties, resulting in
uniform and reproducible fill weight of capsules and tablets. Successful film coating can be
applied onto pellets due to their ideal spherical shape and a low surface area-to-volume ratio.
Pellets composed of different drugs can be blended and formulated in a single dosage
form. This approach facilitates the delivery of two or more drugs, chemically compatible or
incompatible, at the same sites or different sites in the gastrointestinal tract. Even pellets with
different release rates of the same drug can be supplied in a single dosage form. The pelletized
products can improve the safety and efficacy of the active agent. These multiple-unit doses are
usually formulated in the form of suspensions, capsules or disintegrating tablets, showing a
number of advantages over the single-unit dosage system. The pelletized product can freely
disperse in the gastrointestinal tract as a subunit, thus maximizing drug absorption and reducing
peak plasma fluctuation. Consequently, potential side effects can be minimized without
impairing drug bioavailability. Local irritation derived from high local concentrations of a drug
from a single-unit dose, can be avoided.
The most important reason for the wide acceptance of multiple-unit products is the rapid
increase in popularity of oral controlled-release dosage forms. Controlled-release oral solid
dosage forms are usually intended either for delivery of the drug at a specific site within the
gastrointestinal tract or to sustain the action of drugs over an extended period of time. With
pellets, the above mentioned goals can be obtained through the application of coating materials
(mainly different polymers), providing the desired function or through the formulation of matrix
pellets to provide the desired release pattern.
Advantages of pellets 10, 11:
 They can be divided in to desired dosage strength without process or formulation changes.
 When pellets containing the active ingredient are in the form of suspension, capsules, or
disintegrating tablets, they offer significant therapeutic advantages over single unit dosage forms.
 They can also be blended to deliver incompatible bioactive agents.
 They can also be used to provide different release profile at the same or different sites in the
gastrointestinal tract.
 Pellets offer high degree of flexibility in the design and development of oral dosage form like
suspension, sachet, tablet and capsule.
 Pellets disperse freely in GI tract, maximize drug absorption, and minimize local irritation of the
mucosa by certain irritant drugs.
 Improved flow characteristics: Spheres have excellent flow properties which can be used in
automated processes or in processes where exact dosing is required, e.g. tabletting, moulding
operations, capsule filling, and packaging.
 Coating: Coating of granules is often applied for stabilizing active ingredients in the granule or
to control the release of active ingredients. Typical applications in the pharmaceutical industry
are the controlled release medicines. The easiest shape to coat is the sphere due to the absence of
edges. It is also the most economical one to coat as no extra coating material is required to fill
irregularities in the surface of the granules.
 Packing of beds and columns: In certain processes, porous beds or columns are used as
chemical reactors. Spherical particles allow the reproduction of beds with always the same void
volume, surface area and permeability. Calculations and predictions of the process characteristics
also become easier when round particles are used as many equations are based on flows around
symmetrical bodies.
 Density increase: Both the true and the bulk density of granules are increased by spheronising.
This can improve the process and the packaging.
 Marketing: For consumer products, spheronising is sometimes only applied for improved
product appearance and marketing reasons.
 Hardness and friability: Hardness and friability depend on the internal cohesive forces and
surface characteristics. Spheronization increases the hardness and reduces the friability of
granules. This will reduce the amount of fines generated during handling or transportation.
Disadvantages of pellets 10, 11:
 Dosing by volume rather than number and splitting into single dose units as required.
 Involves capsule filling which can increase the costs or tabletting which destroy film coatings on
the pellets.
 The size of pellets varies from formulation to formulation but usually lies between 1 to 2mm.
Desirable properties of pellets 10, 11:
 Uncoated pellets:
1. Uniform spherical shape.
2. Uniform size.
3. Good flow properties.
4. Reproducible packing.
5. High strength.
6. Low friability, Low dust.
7. Smooth surface.
8. Ease of coating.
 Once coated:
1. Maintain all of the above properties.
2. Have desired drug release characteristics.
(a) (b) (c)
Figure no.2: (a) Pellets, (b) Perfect pellet, (c) Coated pellet.
GROWTH MECHANISM OF PELLETS 12, 13:
In order to select and optimize any pelletization/granulation process, it is important to
understand the fundamental mechanisms of granule formation and growth. Different theories
have been postulated related to the mechanism of formation and growth of pellets. The
mechanism of pellet formation and growth, the following steps were proposed:
Nucleation, coalescence, layering and abrasion transfer.
 Nucleation: Nucleation (Figure no.3, A) is a common stage in all pelletization/granulation
processes and occurs whenever a powder is wetted with liquid. The primary particles are
drawn together to form three-phase air-water-liquid nuclei and are attached together by liquid
bridges which are pendular in nature. The bonding strength is improved by reduction of
particle size. The sizes of the primary particles, the moisture content, the viscosity of the
binding particles, the wettability of the substrate and the processing conditions, such as
tumbling and drying rates, influence the size, the rate and the extent of nuclear formation.
Both the mass and the number of nuclei in the system change as a function of time, which is
an important feature of nucleation. Nucleation is followed by a transition phase, and the
growth mechanisms affecting the transition region are coalescence and layering.
 Coalescence: Coalescence (Figure no.3, B) is defined as the formation of large-sized
particles by random collision of well-formed nuclei, and the mechanism requires slight
excess moisture on the nuclear surface. Although the number of nuclei is progressively
reduced, the total mass of the system remains unchanged during this step. Layering (Figure
no.3, C) is a slow growth mechanism and involves the successive addition of fragments and
fines on an already formed nucleus. In the layering step, the number of particles remains the
same, but the total mass in the system increases due to increasing particle size as a function
of time. The fragments or fine particles can be formed by particle size reduction that occurs
due to attrition, breakage and shatter. The fines and the fragments that are produced through
size reduction are picked up by large pellets. Production of fines and subsequent coalescence
and layering continues until the number of favorable collisions declines rapidly, thereby
leading to a reduction in the rate of growth of the pellets. At this point the third phase, the
ball growth region, is reached.
 Abrasion transfer: In the ball growth phase the main mechanism affecting the slow growth
of agglomeration is the abrasion transfer (Figure no.3, D) which involves the transfer of
materials from one granule formed to another without any preference in either direction. This
situation does not result in a change in the total number or mass of the particles. The
particles, however, undergo a continuous change in size as long as the conditions that lead to
the transfer of material exist.
Figure no.3: Pellet growth mechanisms. (A) Nucleation, (B) coalescence,
(C) layering and (D) abrasion transfer.
PELLETIZATION TECHNIQUES 13:
Figure no.4: Different pelletization techniques
Compaction and drug layering are the most widely used pelletisation techniques in
pharmaceutical industry. Of the compaction techniques, extrusion and spheronization is the most
popular method. Recently, however, melt pelletisation has been used frequently in making
compaction pellets using a different type of equipment, e.g. a high-shear mixer. Other
pelletisation methods, such as globulation, balling and compression are also used in the
development of pharmaceutical pellets although in a limited scale.
Extrusion-spheronization 16, 18, 21, 22:
Extrusion-spheronization is a multiple-step compaction process comprising dry mixing of
the ingredients with excipients, wet granulation of the mass, extrusion of the wetted mass,
charging the extrudates into the spheroniser to produce a spherical shape, drying the wet pellets
in a dryer and, finally, screening to achieve the required size distribution. The granulation step
can be performed both in batch-type processors, including a conventional planetary mixer, and
vertical or horizontal high-shear and sigma-blade mixers, and in continuous mixers, such as Nica
and high-shear twin-screw mixer-extruders. General layout of extrusion spheronization is shown
in (Figure no.5).
Figure no.5: Extrusion-Spheronisation Process lay out.
Extruders 17, 20:
A variety of extruders are currently on the market, differing in design features and
operational principles. These can be classified as screw-fed extruders, gravity-fed extruders, and
ram extruders. Screw-fed extruders have screws that rotate along the horizontal axis and hence
transport the material horizontally; they may be axial or radial screw extruders (Figure no. 6).
Figure no.6: Screw fed extruders. A: Axial extruder. B: Radial extruder.
Axial extruders which have a die plate that is positioned axially, basically consists of a
feeding zone, a compression zone, and an extrusion zone. The temperature of the product during
extrusion is controlled by a jacket barrel. In radial extruders, the transport zone is short, and the
material is extruded radially through screens that are mounted around the horizontal axis of the
screws.
Gravity-fed extruders include the rotary cylinder and rotary gear extruders, which differ mainly
in the design of the two counter-rotating cylinders (Figure no.7)
Figure no.7: Gravity fed extruders. A: Rotary-cylinder extruder. B: Rotary-gear
Extruder.
In the rotary-cylinder extruder, one of the two counter-rotating cylinders is hollow and
perforated; whereas the other cylinder is solid and acts as a pressure roller. In rotary gear
extruder, there are two hollow counter-rotating gear cylinders with counter bored holes.
Spheronizer 17, 18, 19, 22:
A spheronizer, known as Marumizer, consists of a static cylinder or stator and a rotating
friction plate at the base. The stator can be jacketed for temperature control. The friction plate, a
rotating disk with a characteristically grooved surface, is the most important component of the
equipment. A standard friction plate with a cross-hatch pattern, where the grooves intersect at a
90o angle, is shown in (Figure no 8).
Figure no.8: Spheronizer friction plate with a cross-hatch pattern.
The width of the grooves should be selected according to the pellet diameter, and is, in
general, 1.5 to twice the target pellet diameter. The diameter of the friction plate is about 20cm in
laboratory-scale equipment and up to about 1m in production-scale units. The rotational speed of
the friction plate is variable, ranging from 100 to 2000rpm, depending on the diameter of the
unit.
The process produces products ranging from barely-shaped, irregular particles like the
conventional granulation, to very spherical particles with drastically different properties.
Tabletting characteristics can be altered by modifying the composition, the granulating fluid or
the process conditions. The main advantage over other methods of producing drug-loaded
spheres or pellets is the capacity to produce spherical pellets of a uniform size and high drug
content up to 90%.
Mechanism of Spheronization 19, 20:
Following (Figure no.9) is the representation of the two models proposed to describe the
mechanism of spheronization. The model proposed by Baert et al, describes a transition from
initial cylindrical particles (A) into a bent rope (B), dumbbell (C), and two spherical particles wit
hollow cavity (D) and spheres (E).
Figure no.9: Mechanism proposed for spheronization
The model proposed by Rowe describes transition from cylindrical particles (F) into
cylindrical particles with rounded edges (G), dumbbell (H), Ellipsoid (I) and spheres (J). Thus
this graphic representation depicts various stages of pellet formation.
Drug layering 7, 8,9,23
The layering process comprises the deposition of successive layers of drug entities from
solution, suspension or dry powder on nuclei that may be crystals or granules of the same
material or inert starter seeds. In solution/suspension layering, drug particles are dissolved or
suspended in the binding liquid. In powder layering, complete dissolution does not occur, due to
low liquid saturation, irrespective of the solubility of the active agent in the binding liquid. In
powder drug layering, a binder solution is first sprayed onto the previously prepared inert seeds,
followed by the addition of powder. (Figure no.10) shows principle of powder layering process.
Figure no.10: Principle of the powder layering process
Figure no.11: Principle of the suspension and solution layering process
A starting grain or a pellet can be presented as the starting material. The pellet is built up
to the required grain size by adding the layering substance one layer at a time. Powder and
binders, suspensions or solutions make suitable layering substances (Figure no.11). The layers
are densely applied due to the movement of the pellets in the rotor (Fluid Bed Pelletizing in the
rotor). Different layers of various types can be applied. Thick layers can be applied to the starting
grains, which, in the case of layers containing active ingredients, allow large amounts of active
ingredient to be incorporated.
Conventional pan coaters 23:
Conventional pan coaters have been used from the very beginning of the history of drug
layering pelletisation. From the economic point of view, however, use of conventional pan
coaters (Figure no.12) is not very reasonable due to the higher labour costs and time
consumption, and lower yield.
Figure no.12: Conventional Pan Coaters
Fluidized-bed Granulators 26, 27:
High level of perfection in shape and size of the granules can not be obtained by
agglomeration mechanism using a conventional fluidized-bed granulator. Modified fluidized -
bed units, such as the Roto-processor, the spir-A-flow, and the Glatt Rotor Granulator / Coater
(Figure no.13), all utilize a rotating disc at the bottom of fluidized-bed, replacing the
airdistribution place. This modification supposedly combines the advantages of the dish
granulator and the fluidized bed granulator.
Figure no.13: Glatt rotary fluid-bed spray granulator dryer
Variable in FBP 36:
Table No.1: Process-Related Variables
a)  Inlet air
temperature
Higher: finer granules.  Lower: Larger, stronger granules.
b) Humidity Increase in humidity: larger granule size, longer drying times.
c) Fluidizing airflow Proper airflow should fluidize the bed without clogging the filters.
Higher airflow will cause attrition and rapid evaporation, generating
smaller granules and fines.
c) Nozzle and
nozzle height
A binary nozzle produces finest droplet and is preferred. Optimum
nozzle height should cover the bed surface. Too close to the bed: will
wet the bed faster, producing larger granules. Too high position:
creates finer granules, and increase granulation time.
e) Atomization air
volume and pressure
Liquid is atomized by the compressed air. This mass/liquid ratio must
be kept constant to control the droplet size, and granule size. Higher
liquid flow rate will produce larger granules and the reverse will
produce smaller granules.
f) Binder spray rate Droplet size is affected by liquid flow rate, binder viscosity, and
atomizing air pressure and volume. The finer the droplet, the smaller
the resulting average granules.
g) Rotor Speed Higher rotation rates resulted in excessive friability of the corers and
loss of the coating powder.
h) Spray rate Lower spray: longer processing time resulting in a lower porosity of
the pellets. Higher spray: higher water content, shorter processing time
and larger pellets, shorter time for liquid to evaporate, broader size
distribution.
i) Moisture content There is sensitive relation between moisture content and particle size,
and moisture sensitivity depends strongly on the formulation,
especially the fraction of pelletization aid.
Centrifugal Granulators 24, 25:
They are routinely used to manufacture pellets by solution, suspension, and powder
layering as well as to produce high potency pellets in a few minutes or hours in contrast to the
long processing times required in a coating pan process, particularly during powder layering.
Centrifugal fluid-bed granulators can be classified as single and double chamber rotary
granulators. Most of these granulators utilize a single-walled product chamber with a rotating
disc at the base (Figure no.14).
Figure no.14: Centrifugal fluid bed equipments.
Other pelletization methods 28:
Other pelletization methods such as globulation, agitation and compaction (compression)
are also used, although in a limited scale, in the preparation of pharmaceutical pellets. Also
recently developed techniques like cryopelletization and melt speronization have been employed
Globulation 28, 29:
Globulation, or droplet formation, consists of two related processes, spray drying and
spray congealing. Spray drying is the process in which drugs in the suspension or solution
without excipient are sprayed into a hot stream to produce dry and more spherical particles. This
process is commonly used for improving the dissolution rates; hence bioavailability of poorly
soluble drugs Principle of spray globulation is depicted in (Figure no. 15).
Figure no.15: Principle of Spray Granulation (Globulation)
Compression 28, 29:
Compression is one type of compaction technique for preparing pellets. Pellets of definite
sizes and shapes are prepared by compacting mixtures or blends of active ingredients and
excipients under pressure. The formulation and process variables controlling the quality of
pellets prepared are similar to those used in tablet manufacturing.
Balling 28, 29:
Balling is the pelletisation process in which pellets are formed by a continuous rolling
and tumbling motion in pans, discs, drums or mixers. The process consists of conversion of
finely divided particles into spherical particles upon the addition of appropriate amounts of liquid
(Figure no.16).
Figure no.16: Principle of spherical agglomeration (Balling)
Film-formers for enteric resistance coating 31, 32,33,34,35:
Polymers are macromolecules having a molecular weight range between 10,000 and
several million Daltons and consist of a number of repeating units in the structure. They can
cause a prolonged drug release in order to extend the intake intervals or enteric resistance in
order to protect the drug against the acidic media in the stomach.
Shellac:
The oldest group of polymers for enteric resistance coating, consists only on shellac,
which is of natural origin and has been used for hundred years for enteric coatings and taste
masking as well as prolonged release. Shellac is obtained from the resinous secretion of the
insect Kerria lacca. Due to higher coating levels shellac is able to retard the drug release, but
these formulations lack of drug release in the gastric environment. Shellac consists mainly of a
mixture of polyesters, basically composed of shelloic and alleuritic acid, which are responsible
for its gastric resistance properties. However, as a product of natural origin it is subjected to
batch-tobatch variation of the quality in dependence of the purification process and the resulting
content of wax, coloring material and other impurities. According to the literature coating
materials such as shellac and resin do not fulfill modern requirements because they are not
sufficiently soluble in the digestive tract. Incorporation of hydrophilic polymers into the shellac
formulation, according to the study conducted by Qussi and Suess, 2005, could prevent
dissolution of drug in simulated gastric fluid for 2 hours and increase the drug release from
pellets.
Aqueous dispersion:
Aqueous dispersions are dispersed substances in the dispersing agent, water like gas in
water (foam), fluid in water (emulsion), or solid in water (suspension). When the dispersed phase
is a polymer, it is called polymer dispersion and the dispersed phase can be solid, fluid or any
intermediate condition. The term latex is used for colloidal polymer dispersions. The aqueous
systems have an advantage from an environmental standpoint and are less toxic and cheaper than
organic systems. The particle size is the most important specification of latex and is between 10
and 1000 nm. Latexes are characterized by low viscosity even when they have high solid content
like 30%.
Methacrylic acid copolymers:
Methacrylic acid copolymers belong to a group of polymers which are insoluble in acid
media and dissolve by salt formation above pH 5-6. They are full synthetic copolymers
exhibiting an acidic carboxyl group which is responsible for the enteric resistance. The backbone
is based on a continuous carbon chain stabilized by methyl groups resulting in poly(methyl
methacrylate) (PMMA) which was also used crystal clear, unbreakable organic glass.The enteric
resistant polymer is available as Eudragit® L and S. Hence they are used for enteric film
coatings, since they are insoluble in dilute acids, gastric fluid and pure water, they dissolve in
buffer solutions above pH 5.5 (L 100-55), pH 6 (L 100) and pH 7 (S 100). Methacrylic acid
copolymers are produced by emulsion polymerization and subsequent spray drying. They are
soluble in isopropyl alcohol, acetone, ethanol and methanol, also in mixtures with up to 40%
water.
These products are commercially available in the form of spray-dried powders, and in the
form of aqueous dispersion with 30% solids (Eudragit L 30 D-55). Eudragit L 30 D-55 is an
anionic copolymer based on methacrylic acid and ethyl acrylate, with free carboxyl groups in a
ratio of 1:1 with the ester groups. The carboxylic groups begin to ionize in an aqueous media at
pH 5.5 and above, rendering the polymer resistant to the acidic environment of the stomach, but
soluble in intestinal fluid. With aqueous dispersions, the process conditions such as spraying rate,
drying temperature, amount of drying air and spraying pressure must be carefully chosen because
if, as a result of processing conditions, the product bed temperatures are too low, they will be
insufficient to achieve the desired filming above minimum film-forming temperature. The
product temperature during coating should be approximately 20°C above the minimum film
formation temperature in order for good film formation to occur. On the other hand, excessively
high product bed temperatures allow the dispersion agent to evaporate so rapidly that the film
former is spray dried.
Important reasons for enteric coating are as follows:
 To protect acid-labile drugs from the gastric fluid.
 To protect gastric distress or nausea due to irritation from drug.
 To deliver drugs intended for local action in the intestines.
 To deliver drug that are optimally absorbed in the small intestine to their primary absorption
site in their most concentrated form.
 To provide a delayed release component to repeat actions.
 Protect the drugs from harmful effect of the gastric contents; some of the drugs are prone to
be hydrolyzed in acid media (E.g. Esomeprazole, omeprazole, pantaprazole).
Ideal enteric coating materials should have the following properties:
 Resistance to gastric fluids.
 Ready susceptibility to or permeability to intestinal fluids.
 Compatibility with most coating solution components and the drug substrates.
 The film should not change on aging.
 Formation of continuous film.
 Non-toxicity.
 Low cost.
 Ease of application.
Excipients for pellets 32, 33, 34, 35:
Formulation aids or excipients are added to pharmaceutical dosage forms mainly to
produce satisfactory delivery of the drug to the intended site, to impart favorable characteristics
to the dosage form and to facilitate the manufacture of the product. Since pellets are intended to
be administered orally, the excipients used in the pellet dosage forms are typically the same as
those used in tablet or capsule formulations.
Excipients, disintegrant, surfactants, pH adjusters, Separating agents, Spheronization
enhancers, glidants and release modifiers etc. some examples of such excipients are given in
Table no.2.
Table No.2: Examples of commonly used excipients
Characterization of pellets 37, 38, 39:
In order to meet the requirements of size distribution, surface area, shape, surface
roughness, density and friability, including the reproducibility of morphologic properties of the
pellets, pellets have to be tested.
Size distribution 42, 45, 51:
The size distribution of pellets should be as narrow as possible because it will ensure a
minimum variation in coating thickness and coating performance within the batch. If the pellets
are intended for compression, wide size distribution may lead to segregation and variations in
content uniformity. The most common and widely used method for determination of size
distribution is sieve analysis. The reasons for its extensive use are simplicity, low costs, low time
Filler MCC, Starch, sucrose, lactose, mannitol
Binder Gelatin, HPC, HPMC, MC, PVP, Sucrose, starch
Lubricant Calcium stearate, glycerin, PEG, Mg. stearate
Separating agent Kaolin, talc, silicon dioxide
Disintegrant Alginates, croscarmellose sodium
PH adjuster Citrate, phosphate, meglumine
Surfactant Polysorbate, Sodium lauryl sulphate
Spherinization enhancer MCC, Sodium carboxy methyl cellulose
Glidant Talc, starch, Magnesium stearate
Release modifier Ethyl cellulose, carnauba wax, shellac
consumption. Some of the disadvantages of this simple method are the inability of the sieve to
detect variation in the shapes of particles. The procedure involves the mechanical shaking of a
sample through a series of sieve sizes and weighing these sieves before and after the analysis.
Critical parameters of the method are sieve loading, type of motion (vibration or tap), intensity
and duration of intensity. Another method for measurement of pellet size distribution is light
scattering, and which is most suitable method for spherical particles. In laser diffraction method
particles pass through a beam of light, they scatter the light, which is directed onto a diode array
detector directly opposite the incident light. Sizing of the particles is based on the angle of
diffracted light, with small particles diffracting at wider angles than larger particles. Assuming a
log-normal distribution, a plot of particle size versus the cumulative percentage of undersize
particles can be used to determine the geometric mean weight diameter dg, the size
corresponding to the 50% value, which is also equal to the mean diameter Randall, 1995. When
making a log-probability plot it is common to find that experimental data are scattered, specially
the one with very small and very large particles. For this reason when determining the best
straight line, it is recommended by some authors that only experimental points within the 20 to
80% range are used.
Shape and surface roughness 45, 46:
In order to obtain good performance of coated pellets it is necessary to have spherical and
smooth particles suitable for subsequent coating, usually for achieving modified-release. The
commonly used method is the analysis of microscopic or non-microscopic pictures of interest.
Scanning electron microscopy (SEM) is a technique of choice for measuring the shape and
surface smoothness of the pellets to support visually the other qualitative and quantitative results.
Porosity 45, 46:
The morphology of pellets and total structure can change in any variation in formulation
or material properties, affecting porosity, which is considered to have a great influence on
coating, flow and packing during tablet or capsule filling Rashid, 2001. It also influences the rate
of release of drug from pellets by affecting the capillary action of dissolved drug (Rashid, 2001).
The pores can be analyzed, qualitatively, by scanning electron microscopy and, quantitatively by
mercury porosimetry. The “PoreSizer” measures the volume distribution of pores in material by
mercury intrusion or extrusion. It is a 30,000 psia (207MpA) mercury porosimeter covering the
pore diameter range from approximately 360 to 0.006 μm / 3 nm to 200 μm. The unit has two
built-in low pressure ports (range of low pressure measurement 0 to 30 psia which corresponds
to pore diameter 360 to 6 μm) and one high pressure chamber (with the high pressure
measurement range of 0 – 30 000 psia which corresponds to pore diameter 6 – 0.006 μm).
Mercury has a high surface tension and is non-wetting to all materials with exception of a few
noble materials. These properties cause a mercury surface in contact with a solid to assume the
minimum surface area and the largest radius of curvature possible at a given pressure. An
increase in pressure on the mercury shifts the balance between surface tension and surface area
causing the radius of the curvature of the mercury contacting the solid to become smaller. When
the radius is equal to that of a pore entrance, mercury fills the volume within the pore. The
method is based on the capillary rise phenomenon in which excess pressure is required to force a
non-wetting liquid into a narrow volume. The mercury is forced into the pores of the sample
using an externally applied pressure, with the smallest pores requiring the highest pressure to
affect the filling.
Density of pellets 48:
Variation of density of pellets from batch to batch affects the potency of finished
capsules, produces segregation during mixing and causes problems in batch size determination
during coating.
Bulk and tap density of pellets is measured using automated tapper, by measuring the
volume of a known mass into a graduated cylinder, and is influenced by the diameter and size
distribution of pellets. They are indicative of the packing properties of particles. True density
indicates the extent of densification or compactness of substance. The pycnometric density is
determined by measuring the volume occupied by a known mass of particles which is equivalent
to the volume of gas displaced by the particles. In this case only open pores are included in the
measured volume since the sealed pores are inaccessible to the gas.
In-vitro dissolution testing 40, 41, 55, 56:
Dissolution is defined as the process by which a solid substance enters in the solvent to
yield a solution. A dissolution test measures the rate of release of the drug. Before the drug is
absorbed from the gastrointestinal tract (GIT), it has to be released and dissolved first. For a
development compound, dissolution testing is used primarily to help and evaluate new
formulations by evaluating the drug release from dosage forms, evaluating the stability of these
formulations, but for the commercial products dissolution testing is used primarily to confirm
manufacturing and product consistency and to assess post-approval changes and the need for
bioequivalence studies (Brown et al., 2004).
Friability 49:
The essential requirement of pellets is to have an acceptable friability to withstand further
processing, especially the subsequent coating. A high amount of attrition during the coating
procedure could modify the release behavior due to the incorporation of small particles in the
film40 friability of less than 0.08% is generally accepted for tablets, but for pellets this value
Flowability 48, 49:
By angle of repose Ө<25 to 30- excellent Flowability, Ө>40 to 60 - poor flowability.
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 Fellenius et al, 1981, explained Substituted Benzimidazoles Inhibit Gastrointestinal Acid
Blocking H.sup.+-ATPase,
 Bjorn Wallmark et al, 1985, explained the relationship between gastric acid secretion and
gastric H+, K+, ATPase activity.
 Meyer UA. et al, 1996, analyzed the metabolism of proton-pump inhibitors lansoprazole,
omeprazole and pantoprazole by cytochrome P450 (CYP) enzymes, and consequences for
drug-drug interactions.He concluded that Proton-pump inhibitors interact with and are
metabolized by several human cytochromes P450, but only pantoprazole is also metabolized
by a sulfotransferase. This may partlt explain why, in this group of proton-pump inhibitors,
pantaprazole has the lowest potential for interactions with other drugs.
 Fryklund et al, 1988, studied the Function and Structure of Parietal Cells After H.+ /K+-
ATPase Blockade,
 Sean R. Tunis et al, 1997, compared “Lansoprazole with histamine2-receptor antagonists in
healing gastric ulcers: A meta-analysis” shows that lansoprazole heals ulcer more quickly
than do the H2RAs and also achieved higher overall rates of healing.
 Jae-Wook Ko et al, 1997, Evaluated of Omeprazole and Lansoprazole as inhibitors of
cytochrome P450 isomers.
 Hasebe T et al, 1998, investigated of the differences in background factors, clinical features,
and gastric function tests among gastric ulcers of various depths. They concluded that
smoking, alcohol consumption, recurrence of ulcers, hyperacidity and H.pylori infections are
important factors associated with deep ulcers.
 M. Marvola et al., (1998), developed a multiple unit site specific drug formulation allowing
targeting of drug release in the colon by enteric polymer as binders and coating materials.
Ibuprofen and furosemide were the model drugs. Methacrylate copolymer, hydroxpropyl
methylcellose acetate succinate and cellulose acetate phthalate were used as enteric polymer.
The main conclusion was that drug release can be targeted on the distal part of the small
intestine and the colon by preparing film-coated matrix pellets in which enteric polymers
dissolving at PH have been used both as binders in the pellets and as coating material.
 US Patent by Lundberg et al, 2000, explained new pharmaceutical dosage form comprising
a core material that contains a proton pump inhibiter, one or more alkaline reacting
compounds and optionally pharmaceutical excipients having a water soluble separating layer
and an enteric coating layer.
 J. Jaime Caro et al, 2001, explained Healing and relapse rates in gastroesophageal reflux
disease treated with newer proton-pump inhibitors Lansoprazole, Rabeprazole and
pantoprazole compaired with omeprazole, ranitidine and placebo: evidence from randomized
clinical trials.
 Robinson M. et al, 2001, studied ‘New-generation proton pump inhibitors: overcoming the
limitations of early-generation agents,When the two newest PPIs, rabeprazole and
esomeprazole, are compared with the old drugs in this class (omeprazole, lansoprazole and
pantoprazole), the newer PPIs offer several key advantages over older agents, particularly in
terms of the management of gastro-esophageal reflux disease. Rabeprazole and esomeprazole
achieve more rapid and profound inhibition of acid secretion than do older agents, and they
sustain this suppression to provide acid control and symptom relief over 24h.
 Gerson et al, 2001, studied Protonpump inhibitors and their drug interactions: an evidence
based approach.
 Us Patent By Hsiao et al, 2002, explained method for preparing an oral formulation
consisting acid sensitive drugs, including at least the following step : spreading a solution or
a suspension containing at least stabilizers, solvents and acid sensitive drugs or its
pharmaceutically acceptable salts on to a core made from one or more excipients , and then
drying the core to make an active ingredients layer over the core.
 Anan S. Raghunath et al, 2003, explained the clinical and economic impact of using
Esomeprazole or Lansoprazole for the treatment of erosive esophagitis.
 Us patent By Chen, 2004, investigated New stable enteric coated pharmaceutical dosage
form for oral use containing omeprazole or lansoprazole, to a formulation and a method for
the manufacture of such a dosage forms, and to a method of gastric acid pump inhibition and
providing gastrointestinal cytoprotective benefit by using them.
 Stephen Levine et al, 2004, explained the use of Acrylic resins for improved aqueous enteric
coating.
 J.W.Devlin et al, 2005, explained ‘Proton pump inhibitors for acid suppression in the
intensive care unit: Formulary considerations’
 John W Devlin et al, 2005, used an evidence-based approach, the linical efficacy, safety, and
cost-effectiveness of proton pump inhibitors (PPIs) for treatment of common acid peptic
disorders in the acutely ill and provide clinicians with guidance when making hospital
formulary decisions with this class of agents. They conclude while the introduction of new
proton pump inhibitor products has expanded the therapeutic options for acid suppression in
acutely ill patients, a number of unresolved significance of one PPI formulation over the
other, and how oral/enteral therapy should be used as step-down therapy after parenteral
therapy.
 D. Sreedhar et al, 2001, introduced Proton Pump Inhibitors, for the treatment of heartburn,
ulcers and Gastroesophageal reflux disease (GERD).
 Vinod P. Shah et al, explained dissolution profile comparison and its impact.
 Harun Ar Rashid et al., studied the influence of the centrifugal granulating process on the
properties of layered pellets. The study was to characterize the effect of three variables that is
rotor rotation speed slit air flow rate and spray air rate on the properties of the drug layered
pellets prepared with MCC beads as substrates using 33 full factorial experimental design.
The responses studied were the amount of drug loss during the process and the amount of
agglomerates, bulk density, flowability, as well as the shape and surface roughness of the
pellets.
 Wong DT, Robertson DW, Bymaster FP, Krushinski JH, Reid LR., worked on influence of
subcoat application and micro-environmental pH on the dissolution properties of enteric
coated sodium valproate pellets was investigated. The pellets were prepared by solution-
layering or wet-mass extrusion-spheronization methods. In order to pass the USP enteric test,
the solution-layered and wet-mass extruded pellets required 35 and 25% weight gain of
EudragitL 30D-55, respectively. The application of a subcoat of either Methocel-E5 (HPMC)
or Opadry AMB to the pellets resulted in a delay in sodium valproate release in 0.1N HCl.
Further delay in drug release was observed when citric acid was present in a HPMC subcoat
or when added to the core pellet formulation. The amount of drug released from coated
pellets was a function of the level of citric acid in the pellet core or subcoat and subsequent
micro- environmental pH of the pellets. Citric acid exerted a plasticizing effect on the enteric
polymer film and improved film formation and polymer coalescence. When greater than 10%
(w/w) citric acid was present in the pellets, a decrease in drug content was observed due to
the conversion of sodium valproate to the volatile compound, valproic acid. Pellets
containing less than 10% (w/w) citric acid maintained potency during processing31.
 Md A Rahman, J Ali et al, studied the multiparticulate formulation of sodium para
aminosalicylate for oral administration was developed by extrusion spheronization technique.
Microcrystalline cellulose was used as filler in concentration of 14.4% w/w. Pellets were
coated with Eudragit L 30 D-55 using fluidized bed processor. Different weight gains of
acrylic polymer were applied onto the pellets and evaluated for in vitro dissolution behavior
in 0.1 N HCl for two hours and then media was changed to phosphate buffer pH 6.8. A 60%
w/w coating level of Eudragit L30 D 55 has produced the most acceptable results against the
gastric attack. 3% Seal coat of HPMC E5 was also applied in order to protect the drug from
migration into the Eudragit coat and film coat was applied in order to prevent aggregation of
pellets in the dissolution media. Morphological characteristics of developed pellets were also
investigated by scanning electron microscopy and found to be smooth and spherical.
Developed system was found to be suitable for the delivery of Sod PAS in to intestinal
region39.
 MC Gohel, KG Sarvaiya et al, explained the objective of the present work was to formulate
the enteric minitablets of isoniazid by cold extrusion method. The minitablets were prepared
using isoniazid, hydroxylpropylmethylcellulose phthalate and dibasic calcium phosphate.
The minitablets were coated using hydroxypropylmethylcellulose phthalate. Full factorial
design was adopted to optimize the formulation. The minitablets showed good flow and
acceptable friability. The drug release was resisted in 0.1 N HCl for 2 h from the optimized
batch. The optimized batch showed more than 90% of drug release in phosphate buffer in 15
min. Capsules containing rifampicin powder and enteric isoniazid minitablets showed
complete drug release in acidic and alkaline media respectively. The process of cold
extrusion appears to be an attractive alternative to by-pass the existing patents38.
 S. C Basak, K Kaladhar, T Subburaj et al, reported a delayed release doxycycline hyclate
capsules were prepared with suitable blend of doxycycline hyclate-coated nonpareil seed
pellets and doxycycline hyclate delayed release pellets. The delayed release pellets were
prepared by coating the doxycycline hyclate-coated pellets with
hydroxypropylmethylcellulose phthalate-55 polymer solution. A concentration of polymer in
the range of 15 to 20% was found to comply with drug release test as specified in the USP in
acid medium but failed to meet the requirements in buffer medium (pH 5.5). The inclusion of
sodium starch glycolate (1-3%) in both doxycycline-coated and delayed release pellets
preparation stages was found to enhance the release of the drug in the buffer medium without
altering its release in acid medium. The blend of delayed release pellets (75%) and drug-
coated pellets (25%) in delayed release doxycycline hyclate capsules produced an optimum
in vitro drug release in both the media.
 Lin. et al. (2004), studied hydrophilic excipient like HPMC, spray-dried lactose modulate the
time lag of time-controlled disintegrating press-coated tablet. They reported that the lag time
markedly dependent in the weight ratio of Ethyl cellulose (EC)/ spray dried lactose or
EC/HPMC in the outer shell. Different time lags of the press coated tablets from 1 to 16.3
hours could be modulated by changing the type and amount of excipients. A semi
logarithmic plot of the time lag of the tablet against the weight ratios of (EC)/SDL or
EC/HPMC in the outer shell demonstrated a good linear relationship, with r = 0.976 and r =
0.982, respectively.
 Bai et al,(2005), invented a pulsatile drug delivery system comprising of plurality of particle
that are divided in to several individual delivery units, each having it's own distinct
composition. Drug delivery was controlled by the rupture of the membrane. The timing of
release was controlled by the thickness of coating and the amount of water soluble polymer
to achieve the pulsed release. The individual particles had the same composition of internal
core, but the thickness of the external coating layer varied.
 J. Siepmann. et al., 2007, studied the use of polymer blends as coating material for
controlled drug delivery system and their advantages. But these systems are more complex
than coatings based on only one polymer. The blended polymers can be incompatible and
care has to be taken using these types of formulations.
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AIM OF THE STUDY
The aim of the present study was to formulate anti ulcer drug Lansoprazole as a delayed
release multiple unit particulate system (pellets) and study the invitro release pattern.
Anti ulcer drugs under the category of proton pump inhibitor are acid labile drugs. These
drugs will degrade in acidic environment and will lead to therapeutic inefficacy. It is necessary to
bypass the acidic pH of the stomach which can be achieved by formulating delayed release
dosage forms (single unit or multiple units) by using different enteric polymers.
Lansoprazole is a acid labile drug and it will degrade in acidic environment. Therefore to
bypass the acidic pH of the stomach Lansoprazole is formulated as enteric coated pellets.
The present work was carried out for preparation of lansoprazole enteric coated pelletes
to prevent drug release in stomach.
OBJECTIVE
 The objective of the work is to develop a stable, pharmaceutically equivalent, robust and
delayed release pellet formulation of Lansoprazole, which is an orally administered antiulcer
drug
 Pellets are of great interest to the pharmaceutical industry for variety of reasons. Pelletized
products not only offer flexibility in dosage form design and    development, but are also
utilized to improve safety and efficacy of bioactive   agents.
 To formulate and evaluate multiple unit particulate system of anti ulcer drug.
 To study the release profile of the dosage form and to compare their drug-release profiles
with the innovator.
 To study the stability of dosage form.
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Present work was carried out to design and evaluate the enteric coated pellets of
Lansoprazole.
The study was proposed to carry out in the following stages
Phase-1
 Preformulation study of  lansoprazole
 Preparation of standard curve of  lansoprazole
Phase-2
 Formulation of enteric coated pellets
 Evalution of enteric coated pellets
 Friability test
 Bulk and Tapped Density
 Angle of repose
 Particle size determination
 Assay study
 Gastric acid resistant test
 Invitro Dissolution study
 Scanning electron microscopy
 Comparison study with marketed formulation.
Phase-3
 Accelerated stability studies.
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DRUG PROFILE:
LANSOPRAZOLE 5, 6,58,59,60:
Appearance:
Lansoprazole is a white to brownish-white odorless crystalline powder.
Chemical IUPAC Name:
2-[(3-methyl-4-(2,2,2-trifluoroethoxy) pyridin-2-yl) methylsulfinyl] -1H-benzoimidazole.
Chemical Formula:
C16H14F3N3O2S
Molecular Weight:
369.363
Molecular structure:
Solubility:
Lansoprazole is freely soluble in dimethylformamide; soluble in methanol; sparingly
soluble in ethanol; slightly soluble in ethyl acetate, dichloromethane and acetonitrile; very
slightly soluble in ether; and practically insoluble in hexane and water.
Melting point:
178-182 oC
Half life:
1.5 (± 1.0) hours
Pharmacology of lansoprazole
Mechanism of Action:
Lansoprazole belongs to a class of antisecretory compounds, the substituted
benzimidazoles, that do not exhibit anticholinergic or histamine H2-receptor antagonist
properties, but rather suppress gastric acid secretion by specific inhibition of the (H+,K+)-ATPase
enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is
regarded as the acid (proton) pump within the parietal cell, Lansoprazole has been characterized
as a gastric acid-pump inhibitor which blocks the final step of acid production. This effect is
dose-related and leads to inhibition of both basal and stimulated gastric acid secretion
irrespective of the stimulus.
Pharmacokinetics:
Absorption:
The absorption of lansoprazole is rapid, with mean Cmax occurring approximately 1.7
hours after oral dosing, and relatively complete with absolute bioavailability over 80%.
Distribution:
Lansoprazole is 97% bound to plasma proteins. Plasma protein binding is constant over
the concentration range of 0.05 to 5.0 µg/ml.
Metabolism:
Lansoprazole is extensively metabolized in the liver. Two metabolites have been
identified in measurable quantities in plasma (the hydroxylated sulfinyl and sulfone derivatives
of lansoprazole). These metabolites have very little or no antisecretory activity. Lansoprazole is
thought to be transformed into two active species which inhibit acid secretion by blocking the
proton pump [(H+, K+)-ATPase enzyme system] at the secretory surface of the gastric parietal
cell. The two active species are not present in the systemic circulation. The plasma elimination
half-life of lansoprazole is less than 2 hours while the acid inhibitory effect lasts more than 24
hours. Therefore, the plasma elimination half-life of lansoprazole does not reflect its duration of
suppression of gastric acid secretion.
Excretion:
Following single-dose oral administration of Lnsoprazole, virtually no unchanged
lansoprazole was excreted in the urine. In one study, after a single oral dose of 14C-lansoprazole,
approximately one-third of the administered radiation was excreted in the urine and two-thirds
was recovered in the feces. This implies a significant biliary excretion of the lansoprazole
metabolites.
Side Effects:
Lansoprazole is well tolerated. A low incidence of events has been reported during
clinical trials in 7867 patients treated with lansoprazole. These events, which are generally
transient and self limiting, include headache, fatigue, malaise, diarrhoea, abdominal pain,
dyspepsia, nausea, vomiting, dizziness, constipation, flatulence, dry or sore mouth or throat, rash,
upper respiratory tract infections, urinary tract infections, arthalgia, and myalgia. Dermatological
reactions include urticaria and pruitus. These generally resolve on discontinuation of drug
therapy. Serious dermatological reactions are rare but there have been occasional reports of
erythematous or bullous rashes including erythema multiforme. Cases of hair thining and
photosensitivity have also been reported. Other reported reactions include jaundice, hepatitis,
interstitial nephritis (sometimes resulting in renal failure.), anaphylaxis, wheezing, angioedema,
bruising, purpura, petechiae, depression, peripheral oedema, paraesthesia, blurred vision, taste
disturbance, vertigo, confusion and hallucinations. Gynaecomastia and impotence may occur
with long term use. During clinical trials a small number of patients developed abnormal liver
function tests while on lansoprazole, however routine monitoring of liver function tests is not
required.
Overdose:
There is no information on the effect of acute over dosage. In case of overdose,
supportive and symptomatic therapy should be initiated.
Dosage up to 180 mg/day for more than a year has been used to treat Zollinger Ellison
Syndrome with no serious adverse effects.
Uses:
 Anti-Infective Agents
 Anti-Ulcer Agents
 Enzyme Inhibitors
 Proton-pump Inhibitors.
EXCIPIENT PROFILE
SUGAR SPHERES 33, 34:
Non Proprietary Names:
BP: Sugar Spheres ; PHEUR: Sacchari sphere,USP : Sugar Spheres.
Synonyms:
Non-Pareil, Non-Pareil seeds, NPTAB, Nu-Core, Nu-Pareil PG, Sugar seeds, Suglets.
Description:
The USPNF23 describes sugar spheres as approximately spherical granules of a labeled
nominal size range with a uniform diameter & containing not less than 62.5% and not more than
91.5% of sucrose, calculation on dried basis.
Category:
Tablet and Capsule diluents.
Density:
1.57-1.59 g/cm3for suglets less than 500 μm in size. 1.55-1.58 g/cm3for suglets more
than 500 μm in size.
Solubility:
Solubility in water varies accordingly to the sucrose to starch ratio. The sucrose
component is freely soluble in water, whereas the starch component is practically insoluble in
cold water.
Flowability:
<10 seconds, free flowing.
Applications:
Sugar spheres are mainly used as inert cores in capsule and tablet formulations,
practically multiparticulate sustained release formulations. Sugar spheres are also used in
confectionery products.
Stability and Storage:
Sugar spheres are stable when stored in a well closed container in a cool dry place.
Incompatibility:
Metals, which can lead to incompatibility with active ingredients Eg: Ascorbic acid.
Sucrose may also be contaminated with sulfite from the refining process. In the presence of
dilute or concentrated acids,sucrose is hydrolyzed or inverted to dextrose and fructose (Invert
sugar). Sucrose may attack aluminium closures.
EUDRAGIT L30 D-55 31, 34, 61:
Non Proprietary Names:
Methacrylic Acid - Ethyl Acrylate Copolymer (1:1) Dispersion 30 Per Cent" Ph. Eur.
"Methacrylic Acid Copolymer Dispersion" USP/NF  "Methacrylic Acid Copolymer LD" JPE
Chemical Name:
Poly (methacylic acid-co-ethyl acrylate) 1:1
Molecular Weight:
250,000.
Structural formula:
EUDRAGIT® L 30 D-55 is the aqueous dispersion of an anionic copolymer based on
methacrylic acid and ethyl acrylate.
The ratio of the free carboxyl groups to the ester groups is approx. 1:1.
Category:
Film former; tablet binder; tablet diluent.
Description:
Milky-white liquid of low viscosity with a faint characteristic odour.
PH:
2.1 - 3.0.
PURITY:
Sulphated ash / Residue on ignition:
Max. 0.12 % according to Ph. Eur. 2.4.14 or USP <281>. 1 g EUDRAGIT® L 30 D-55 is
used for the test. Max. 0.10 according to JPE. 2 g of EUDRAGIT® L 30 D-55 are used for the
test.
Heavy metals:
Max. 20 ppm according to Ph. Eur. 2.4.8 method C or USP <231> method II. 1 g
EUDRAGIT® L 30 D-55 is used for the test.
Arsenic:
Max. 1 ppm according to JP method 3, Apparatus B. 2.0 g EUDRAGIT® L 30 D-55 are
used for the test.
Monomers:
Max. 100 ppm according to the Ph. Eur. or USP/NF monographs.
Microbial count:
Max. 1,000 CFU / g; Salmonella not detectable in 10 g, E. coli, S. aureus, Ps. aeruginosa
not detectable in 1 g. The test is performed according to Ph. Eur. 2.6.12 and 2.6.13.
Characteristics:
Polymethacrylates are primarily used in oral capsules,&tablet formulations as film
coating agents. Effective and stable enteric coatings with a fast dissolution in the upper bowel.
Granulation of drug substances in powder form for controlled release. Site specific drug delivery
in intestine by combination with EUDRAGIT  L30 D55 grades.
Solubility:
The dispersion is miscible with water in any proportion, the milky-white appearance
being retained. A clear or slightly cloudy, viscous solution is obtained by mixing 1 part
EUDRAGIT® L 30 D-55 with 5 parts acetone. The same results are obtained by mixing with
ethanol or isopropyl alcohol; initially, the polymer is precipitated, but then dissolves again in the
excess organic solvent. A clear or slightly cloudy liquid is obtained by mixing 1 part
EUDRAGIT® L 30 D-55 with 2 parts 1 N sodium hydroxide.
Stability&Storage:
Minimum stability dates are given on the product labels and batch-related certificates of
Analysis.
Protect from warm temperatures (USP General Notices). Protect from freezing. Avoid
contamination during sampling. Containers that have been opened for use should be closed again
immediately and the content used up within the next few weeks.
Incompatability:
Incompatibilities occur with certain polymethacrylate dispersions depending upon the
ionic and physical properties of the polymer and solvent.
HYDROXYPROPYL METHYL CELLULOSE 31, 34:
Synonym:
Hypromellose, Hypromellosum, Methocel.
Description:
Hypromellose is an odorless and tasteless, white or creamy-white fibrous or granular
powder.
Functional category:
Coating agent; film-former; rate-controlling polymer for sustained release; stabilizing
agent; suspending agent; tablet binder; viscosity-increasing agent.
Solubility:
Soluble in cold water, forming a viscous colloidal solution; practically insoluble in
chloroform, ethanol (95%), and ether, but soluble in mixtures of ethanol and dichloromethane,
mixtures of methanol and dichloromethane, and mixtures of water and alcohol. Certain grades of
hypromellose are soluble in aqueous acetone solutions, mixtures of dichloromethane and propan-
2-ol, and other organic solvents.
Melting point:
190–200°C, Glass transition temperature is 170–180°C.
Stability and storage condition:
It is a stable material, although it is hygroscopic after drying.Solutions are stable at pH 3–
11. It should be stored in a well-closed container, in a cool, dry place.
Incompatibilities:
Hypromellose is incompatible with some oxidizing agents. Since it is nonionic,
hypromellose will not complex with metallic salts or ionic organics to form insoluble
precipitates.
Safety:
Hypromellose is generally regarded as a nontoxic and nonirritant material, although
excessive oral consumption may have a laxative effect.
Application:
It is widely used in oral, ophthalmic and topical pharmaceutical formulations.
TITANIUM DI-OXIDE 34, 35, 61:
Synonym:
Anatase titanium dioxide; brookite titanium dioxide; color index number 77891; E171;
Kronos 1171; pigment white 6; rutile titanium dioxide; Tioxide; TiPure; titanic anhydride;
Tronox.
Description:
White, amorphous, odorless, and tasteless nonhygroscopic powder.
Functional category:
Coating agent; opacifier; pigment.
Solubility:
Practically insoluble in dilute sulfuric acid, hydrochloric acid, nitric acid, organic
solvents, and water. Soluble in hydrofluoric acid and hot concentrated sulfuric acid. Solubility
depends on previous heat treatment; prolonged heating produces a less-soluble material.
Melting point:
185°C
Stability and storage condition:
Titanium dioxide is extremely stable at high temperatures. This is due to the strong bond
between the tetravalent titanium ion and the bivalent oxygen ions.
Titanium dioxide should be stored in a well-closed container, protected from light, in a cool, dry
place.
Incompatibilities:
Owing to a photocatalytic effect, titanium dioxide may interact with certain active
substances, e.g. famotidine.
Safety:
Titanium dioxide is widely used in foods and oral and topical pharmaceutical
formulations. It is generally regarded as an essentially nonirritant and nontoxic excipient.
Application:
Titanium dioxide is used as a white pigment in film-coating suspensions, sugar-coated
tablets, and gelatin capsules. Titanium dioxide may also be admixed with other pigments.
TALC 34, 35, 61:
Synonym:
Altalc; E553b; hydrous magnesium calcium silicate; hydrous magnesium silicate;
Luzenac Pharma; magnesium hydrogen metasilicate; Magsil Osmanthus; Magsil Star; powdered
talc; purified French chalk; Purtalc; soapstone; steatite; Superiore.
Description:
Talc is a very fine, white to grayish-white, odorless, impalpable, unctuous, crystalline
powder. It adheres readily to the skin and is soft to the touch and free from grittiness.
Functional category:
Anticaking agent; glidant; tablet and capsule diluent; tablet and capsule lubricant.
Solubility:
Practically insoluble in dilute acids and alkalis, organic solvents, and water.
Stability and storage condition:
Talc is a stable material and may be sterilized by heating at 160°C for not less than 1
hour. It may also be sterilized by exposure to ethylene oxide or gamma irradiation.
Talc should be stored in a well-closed container in a cool, dry place.
Incompatibilities:
Incompatible with quaternary ammonium compounds.
Safety:
Talc is used mainly in tablet and capsule formulations. Talc is not absorbed systemically
following oral ingestion and is therefore regarded as an essentially nontoxic material.
Also, long-term toxic effects of talc contaminated with large quantities of hexachlorophene
caused serious irreversible neurotoxicity in infants accidentally exposed to the substance.
Application:
Talc is used as a lubricant in tablet formulations; in a novel powder coating for extended-
release pellets; and as an adsorbent.
PEG 6000 34, 35, 61:
Synonym:
Carbowax; Carbowax Sentry; Lipoxol; Lutrol E; PEG; Pluriol E; polyoxyethylene glycol,
Macrogol 6000.
Description:
Solid grades (PEG>1000) are white or off-white in color, and range in consistency from
pastes to waxy flakes. They have a faint, sweet odor. Grades of PEG 6000 and above are
available as free-flowing milled powders.
Functional category:
Ointment base; plasticizer; solvent; suppository base; tablet and capsule lubricant.
Solubility:
All grades of polyethylene glycol are soluble in water and miscible in all proportions with
other polyethylene glycols (after melting, if necessary). Aqueous solutions of higher-molecular-
weight grades may form gels. Liquid polyethylene glycols are soluble in acetone, alcohols,
benzene, glycerin, and glycols. Solid polyethylene glycols are soluble in acetone,
dichloromethane, ethanol (95%), and methanol; they are slightly soluble in aliphatic
hydrocarbons and ether, but insoluble in fats, fixed oils, and mineral oil.
Melting point:
55–63°C
Stability and storage condition:
Polyethylene glycols are chemically stable in air and in solution, although grades with a
molecular weight less than 2000 are hygroscopic. Polyethylene glycols do not support microbial
growth, and they do not become rancid. Polyethylene glycols should be stored in well-closed
containers in a cool, dry place. Stainless steel, aluminum, glass, or lined steel containers are
preferred for the storage of liquid grades.
Incompatibilities:
Liquid and solid polyethylene glycol grades may be incompatible with some coloring
agents. The antibacterial activity of certain antibiotics is reduced in polyethylene glycol bases,
particularly that of penicillin and bacitracin. The preservative efficacy of the parabens may also
be impaired owing to binding with polyethylene glycols.
Safety:
Generally, they are regarded as nontoxic and nonirritant materials. Oral administration of
large quantities of polyethylene glycols can have a laxative effect. Therapeutically up to 4 lit. of
an aqueous mixture of electrolytes and high-molecular-weight polyethylene glycol is consumed
by patients undergoing bowel cleansing.
Application:
In film coatings, solid grades of polyethylene glycol can be used alone for the film-
coating of tablets or can be useful as hydrophilic polishing materials. Solid grades are also
widely used as plasticizers in conjunction with film-forming polymers.
In solid-dosage formulations, higher molecular weight polyethylene glycols can enhance
the effectiveness of tablet binders and impart plasticity to granules.
TRI ETHYL CITRATE 34, 35, 61:
Non proprietary Names:
BP : Triethylcitrate, PHEUR : Triethylis citras, USPNF : Triethyl citrate.
Synonyms:
Citric acid,Ethyl ester,Citroflex 2,Citrofol AI,E 1505, Hydrogen CAT, TEC. Chemical
Name:
2-Hydroxy-1,2,3-propanetricarboxylic acid,Triethyl ester.
Empirical formula:
C12H20O7.
Molecular Weight:
276.29.
Structural formula:
Category:
Plasticizer
Applications:
Used to plasticize polymers in pharmaceutical coatings. The coating applications include
capsules, tablet, sustained release dosage form.
Description:
Clear,Odorless,Practically colorless,Oily liquid.
Acid value:
0.02
Boiling Point:
288˚c
Flash point:
155˚c
Solubility:
Soluble 1 in 125 of peanut oil, 1 in 15 of water.Miscible with ethanol (95 %),acetone,and
propan-2-ol.
Viscosity (dynamic):
35.2 mPa s (35.2 Cp) at 25˚c.
Stability and Storage:
Stored in a closed container in a cool, dry location. When Stored in accordance with these
conditions, triethyl citrate is a stable product.
Incompatibilities:
Incompatible with strong alkalis and oxidizing materials.
POLYSORBATE 80 33, 34:
Polyoxyethylene sorbitan fatty acid esters (polysorbates) are a series of partial fatty acid
esters of sorbitol and its anhydrides copolymerized with approximately 20, 5, or 4 moles of
ethylene oxide for each mole of sorbitol and its anhydrides.
SODIUM LAURYL SULPHATE 33, 34:
Sodium lauryl sulfate is an anionic surfactant employed wide range of nonparenteral
pharmaceutical formulations and cosmetics; It is a detergent and wetting agent effective in both
alkaline and acidic conditions. In recent years it has found application in analytical
electrophoretic techniques: SDS (sodium dodecyl sulfate) polyacrylamide gel electrophoresis is
one of the more widely used techniques for the analysis of proteins; and sodium lauryl sulfate
has been used to enhance the selectivity of micellar electrokinetic chromatography (MEKC).
Ineffective against many Gram-negative microorganisms.
DISODIUM HYDROGEN PHOSPHATE 33, 34:
Dibasic sodium phosphate is used in a wide variety of pharmaceutical formulations as a
buffering agent and as a sequestering agent. Therapeutically, dibasic sodium phosphate is used as
a mild laxative and in the treatment of hypophosphatemia. Dibasic sodium phosphate is also used
in food products; for example as an emulsifier in processed cheese.
Chapter-6
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6. MATERIALS AND METHODS
6.1. LIST OF MATERIALS:
Table No.3: List of Chemicals Used
Sr.
No
NAME OF
MATERIAL
MANUFACTURING COMPANY
1 Lansoprazole Enal Drugs Ltd. Hyderabad
2 Sugar spheres (600-
800micron)
Sanmour pharma pvt.ltd,  Mumbai
3 Di-sodium hydrogen
orthophosphate
S.D fine chemicles,pvt.itd
Mumbai
4 Hydroxy propyl  methyl
cellulose  E 5
Himedia laboratories, pvt. Ltd. Mumbai
5 Talcum Loba chemie, pvt. Ltd. Mumbai
6 Polyethylene Glycol
6000
Himedia laboratories, pvt. Ltd. Mumbai
7 Sodium lauryl sulphate S.D fine chemicles,pvt.ltd.
Mumbai
8 Eudragit L-30 D 55 Sanmour pharma pvt.ltd. Mumbai
9 Triethyl citrate Loba chemie, pvt. Ltd. Mumbai
10 Polysorbate 80 Himedia laboratories, pvt. Ltd. Mumbai
6.2. LIST OF EQUIPMENTS:
Table No.4: Instruments Used for Formulation Development
PROCESS EQUIPMENT MANUFACTURER MODEL NO.
Weighing Electronic single pan
balance
Shimadzu BL-204
Sieving
process
Mechanical sifter with
sieve
≠24,30,50,60,80 and
100
Retsec ASL 00
Density Tapped density tester
USP
Electrolab ETD-1020
Blending Blender Rimek 410 AG
Stirring Mechanical stirrer Remi motors
Bombay
RQG- 129 D
Drying Fluidized bed dryer Retch TG 100
PH PH meter Elico India --
Dissolution Dissolution test
apparatus USP
Lab India --
Absorbance UV Lab India UV- 1800
Peak Area HPLC Waters Waters 2965
IR Spectrum FTIR Germany Bruker optic
GMBH
6.3. PREFORMULATION STUDIES 35, 64:
To formulate an ideal formulation, the pre-formulation studies are usually the quantitative
assessment of chemical stability of drug as well as stability in presence of other excipients for a
formulation.
Preformulation may be described as a phase of the research and development process
where the formulation scientist characterizes the physical, chemical and mechanical properties of
new drug substances, in order to develop stable, safe and effective dosage forms. Ideally the
preformulation phase begins early in the discovery process such the appropriate physical,
chemical data is available to aid the selection of new chemical entities that enter the development
process during this evaluation possible interaction with various inert ingredients intended for use
in final dosage form are also considered in the present study.
The following preformulation studies were performed:
 Solubility analysis
 Bulk density
 Tapped density
 Melting point
 Loss on drying
 Identification of  drug- excipient compatibility
6.3.1. SOLUBILITY ANALYSIS 35:
Solubility is important pre-formulation parameter because it affects the dissolution and
bio availability of drug.
Method:
Appropriate quantity of drug was weighed and added to the suitable volume of solvent
like hexane, ethanol, and water.
6.3.2. MELTING POINT 35:
The melting point of lansoprazole was determined by capillary method, using small
quantity of lansoprazole was taken and placed in apparatus and determined the melting point and
matched with standards.
6.3.3. BULK DENSITY 35, 48:
Bulk density is defined as the mass of the powder divided by the bulk volume. Bulk
density largely depends on particle shape, as the particle become more spherical in shape, bulk
density will increase. In addition as the granule size increases bulk density decreases.
Method
A given quantity of the powder was transferred to a measuring cylinder and tapped
mechanically either manually or using some tapping device till a constant volume is obtained.
This volume is bulk volume and it includes the true volume of the powder and the void space
among the powder particles.
Bulk Density = Bulk Mass / Bulk Volume
6.3.4. TAPPED DENSITY 35, 48:
Tapped density was determined by using Electrolab density tester, which consists of a
graduated cylinder. An accurately weighed 5gm sample of powder was carefully added to the
cylinder with the aid of a funnel. The initial volume was noted, and the sample was then tapped
(500,750 or 1250 tapping) until no further reduction in volume is noted or the percentage of
difference was not more than 2% a sufficient number of taps should be employed to assure
reproducibility for the material in question. Volume was noted and tapped density is calculated
using following formula.
Tapped density = Wt. of sample in gm / Tapped volume
6.3.5. LOSS ON DRYING 35, 48:
Determined on 1.000 g by drying in an oven at 100°C to 105°C for 3 hours. Accurately
weighed the substance to be tested. If the sample is in the form of large crystals, reduced the
particle size to about 2 mm by quickly crushing. Tared a glass stopper, shallow weighing bottle
that has been dried for 30 minutes under the same conditions to be employed in the
determination. Put the sample in bottle, replaced the cover, and accurately weighed the bottle and
the contents. By gentle, sidewise shaking, distribute the sample as evenly as practicable to a
depth of about 5 mm. Placed the loaded bottle in the drying chamber. Dried the sample at the
specified temperature from constant weighed. Upon opening the chamber, closed the bottle
promptly, and allowed it to come to room temperature in desiccators before weighing.
The difference between successive weights should not be more than 0.5mg.
The loss on drying is calculated by the formula:
(W2-W3)
% LOD = ----------------------------- X 100
(W2-W1)
Where,
W1 = Weight of empty weighing bottle
W2 = Weight of weighing bottle + sample
W3 = Weight of weighing bottle + dried sample
6.3.6. COMPATIBILITY STUDY 64:
Drug- excipient compatibility studies:
IR spectra of drug, drug and polymers and excipients were obtained by using Bruker
optic GMBH FTIR spectrometer.
Method:
FTIR spectra of pure drug, and its physical mixture were obtained by using KBr pellets
methods. About 2% (w/w) of samples was mixed with potassium bromide (KBr) disc. Each disc
was scanned at a resolution of 4 cm-1 over a wave number region of 400–4000 cm-1 by a FTIR
spectrometer.
6.3.7. CONSTRUCTION OF STANDARD CURVE 64:
Lansoprazole (100 mg) was accurately weighed and dissolved in 100 ml methanol to
form a stock solution (1000 μg/ml). The stock solution was further diluted suitably to get a
working standard solution of concentration 100 μg/ml. This working standard solution was
suitably diluted to give a concentration of 20 μg/ml and this was then scanned in UV range. This
showed an absorption maximum at 281 nm. Aliquots (0.5,1.0,1.5,2.0 and 2.5) ml of working
standard solution (100 μg/ml) corresponding to 5-25 μg were taken in a series of 10 ml
volumetric flask and volume made up with water. The absorbance measurements of these
solutions were carried out against methanol as blank at 281 nm. A calibration curve of
lansoprazole was plotted. The concentration of the unknown was read from the calibration graph
or computed from the regression equation.
6.4. FORMULATION OF LANSOPRAZOLE PELLETS 33, 34, 59, 61:
6.4.1. Different batches of pellets (F1 to F9) were formulated using the ingredient given in the
Table no.5: Formula for lansoprazole pellets:
Batch
no.
F1 F2 F3 F4 F5 F6 F7 F8 F9
Sr.no. Ingredients mg/unit mg/ unit mg/unit mg/unit mg/unit mg/unit mg/ unit mg/unit mg/unit
A DRUG LAYERING
1 Sugar Spheres
(600-800 micron)
135.5 140.5 145.5 150.5 155.5 160.5 165.5 170.5 175.5
2 Lansoprazole,
Usp (Micronized)
30.00 30.00 30.00 30.00 30.00 30.00 30.00 30.00 30.00
3 Di-sodium
hydrogen
Orthophosphate
3.00 3.00 3.00 3.00 3.00 3.00 3.00 3.00 3.00
4 Hydroxy Propyl
Methyl Cellulose
E 5
20 20 25 25 30 30 35 40 40
5 Talcum Powder 10 10 10 10 10 10 10 10 10
6 Polyethylene
Glycol 6000
6 6 6 6 6 6 6 6 6
7 Sodium lauryl
sulphate
1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5
8 Purified water qs qs qs qs qs qs qs qs qs
Total 225 230 240 245 255 260 270 280 285
B SEAL COATING OF
LANSOPRAZOLE
PELLETS
F1 F2 F3 F4 F5 F6 F7 F8 F9
9 Lansoprazole layered pellets 225 230 240 245 255 260 270 280 285
10 Hydroxy Propyl Methyl
Cellulose E 5
20 20 25 25 30 30 35 40 40
11 Polyethylene Glycol – 6000 6 6 6 6 6 6 6 6 6
12 Talc, USP 10 10 10 10 10 10 10 10 10
13 Di-sodium hydrogen
orthophosphate
3.00 3.00 3.00 3.00 3.00 3.00 3.00 3.00 3.00
14 Purified water qs qs qs qs qs qs qs qs qs
Total 264 269 284 289 304 309 324 339 344
C ENTERIC COATING OF LANSOPRAZOLE  PELLETES
15 Eudragit L-30 D 55 70.00 65.00 60.00 55.00 50.00 45.00 40.00 35.00 30.00
16 Triethyl citrate, NF 9.25 9.25 9.25 9.25 9.25 9.25 9.25 9.25 9.25
17 Talc, USP 12 12 12 12 12 12 12 12 12
18 Polysorbate 80, NF 3.75 3.75 3.75 3.75 3.75 3.75 3.75 3.75 3.75
19 Purified water qs qs qs qs qs qs qs qs qs
Total 359 359 369 369 378.75 379 389 399 399
Figure no.17: Process Flow chart
Preparation of Drug Slurry (Lot wise)
Drug loading on the Sugar Spheres in Wurster
Coater using suspension layering technique.
Drying of the DL pellets
Preparation of Seal coating solution.
Seal coating on the Drug loaded pellets
Drying of the seal coated pellets
Preparation of Enteric coating Solution
Enteric coating on the Seal coated pellets in Wurster Coater.
Final Drying of the Enteric coated pellets.
Final Drying of the finished product
Capsule filling in size ‘1’
6.4.2. MANUFACTURING STEPS 7, 8, 9, 67, 69, 70:
STAGE-I: Drug Loading
Preparation of drug loading solution:
Lot wise preparation method
1. Took weighed 1/3rd of the total quantity of dematerialized water in stainless steel vessel and
heat the water up to 80-85ºC.
2. Sodium lauryl sulphate, poly-ethylene glycol 6000, di-sodium hydrogen phosphate was
weighed and added one by one in the water and dissolved.
3. Hydroxyl propyl methyl cellulose was weighed and transferred in hot purified water under
stirring and slurry of HPMC was prepared.
4. Remaining quantity of dematerialized water was added in the hot slurry under stirring to
dissolve HPMC.
5. Cooled the solution up to room temperature under stirring.
6. Checked pH and adjusted pH to 9.0 (Acceptable Range 8.5 – 9.5) if necessary by adding
more buffer.
7. Lansoprazole USP was weighed and added in above solution slowly under stirring; stirred
until uniform slurry to be formed.
8. Then purified talcum was added under stirring.
9. Finally mixed properly for 10 minutes, and passed solution through 100 meshes. Stored the
solution in a well closed container.
In process check:
Table No.6: FBC Parameters
Inlet temp 60ºC
Bed temp 40ºC
Atomizing air pressure 2 bar
Spray Rate 15 ml/min
Drug loading Process
Equipment Used: - Fluid Bed Processor with Wurster facility (bottom spray).
Process parameters are as follows:-
Inlet Air Temperature : 60º C
Product Bed Temperature : 47ºC – 50ºC
Outlet Temperature : 43ºC – 46ºC
Nozzle Diameter : 1.0 mm
Atomization Air Pressure : 2.2 – 2.5 Bar
Spray Rate : 5 gms / min
Final Drying time : 30 mins.
Coated pellets are collected in double polythene lined containers.
STAGE-II: Seal Coating
Preparation method:
1. Took weighed 1/3rd of quantity of dematerialized water in stainless steel vessel and heat the
water up to 80-850C.
2. Poly-ethylene glycol 6000, hydroxyl propyl methyl cellulose was weighed and added one by
one in the water and dissolved.
3. Remaining quantity of purified water was added to the above solution under stirring.
4. Cooled the solution up to room temp under stirring.
5. Purified talcum was added under stirring.
6. Then di-sodium hydrogen orthophosphate was weighed and added under stirring.
7. Finally mixed for 10 minutes, and pass the solution through 100 meshes. Stored the solution
in a well closed container.
8. SEAL COATING OPERATIONS
Process parameters are as follows:-
Inlet Air Temperature : 60º C
Product Bed Temperature : 44ºC – 47ºC
Outlet Temperature : 40ºC – 43ºC
Nozzle Diameter : 1.0 mm
Atomization Air Pressure : 2.2 – 2.5 Bar
Spray Rate : 6 gms / min
Final Drying time : 30 mins
Coated Pellets are collected in double polythene lined container.
STAGE-III: Enteric coating
Preparation of coating solution:
1. Purified water was taken in a stainless steel vessel.
2. Triethyl citrate, polysorbate 80 was weighed and added one by one in the above mentioned
water and dissolved.
3. Purified talcum was weighed and added under stirring.
4. Eudragit L 30 D55 was weighed and adde to the above solution under mild stirring. An
ordinary propeller stirrer suffices. Continue stirring for another 15-20 mins.
5. Filtered the final dispersion through 100 mesh screen only.
6. The dispersion was now ready for use.
7. The dispersion was kept under mild stirring during the coating operation.
Enteric coating process:
Perform enteric coating operations by using the following set of parameters:
Inlet Air Temperature : 45º C
Product Bed Temperature : 34ºC – 37ºC
Outlet Temperature : 36ºC – 39ºC
Nozzle Diameter : 1.0 mm
Atomization Air Pressure : 1.5 – 2.0 Bar
Spray Rate : 10 gms / min
Final Drying time : 30 mins
Coated Pellets were collected in double polythene lined container.
Unloaded & weighed the pellets in double lined polythene bags in clean, tared and
labeled plastic drum & closed (air tight) the bags & drums.
6.5. EVALUATION OF FORMULATED LANSOPRAZOLE PELLETS:
6.5.1. FRIABILITY 49:
There was no standard method established for evaluating friability of pellets. The
friability of pellets was determined by using Roche friabilator. But due to the low weight of the
pellets the mechanical stress applied is less. This can be corrected by adding glass or steal balls
to increase stress. The friability was calculated as percentage weight loss according to the
following equation:-
100X
 weightInitial
 WeightFinal- weightInitialFriability% 
6.5.2. BULK AND TAPPED DENSITY 48:
6.5.2.1. BULK DENSITY 48:
Bulk density is defined as the mass of the powder divided by the bulk volume. Bulk
density largely depends on particle shape, as the particle become more spherical in shape, bulk
density is increase. In addition as the granule size increases bulk density decreases.
Method
A given quantity of the Lansoprazole pellets was transferred to a measuring cylinder and
tapped mechanically either manually or using some tapping device till a constant volume is
obtained. This volume is bulk volume and it includes the true volume of the powder and the void
space among the powder particles.
Bulk Density = Bulk Mass / Bulk Volume
6.5.2.2. TAPPED DENSITY 48:
Tapped density was determined by using Electrolab density tester, which consists of a
graduated cylinder. An accurately weighed 5gm sample of pellets was carefully added to the
cylinder with the aid of a funnel. The initial volume was noted, and the sample was then tapped
(500,750 or 1250 tapping) until no further reduction in volume was noted or the percentage of
difference is not more than 2%.A sufficient number of taps should be employed to assure
reproducibility for the material in question. Volume was noted and tapped density was calculated
using following formula.
Tapped density = Wt. of sample in gm / Tapped volume
6.5.3. HAUSNER’S RATIO 48:
It is measurement of frictional resistance of the drug. The ideal range should be 1.2 –1.5.
It is the determined by the ratio of tapped density and bulk density.
Where    vt = Tapped volume
vi = untapped volume
Hausner’s ratio = vi/ vt
Limits:
Table no.7: limits of Hausner’s ratio value
S.No Hausner’s ratio Flow
1 1-1.2 Free flowing
2 1.2-1.6 Cohesive powder
6.5.4. ANGLE OF REPOSE 35, 48, 49:
Angle that can be obtained between the free surface of a powder heap and horizontal
plane. The angle of repose was measured by allowing the pellets to fall over a graph sheet placed
on horizontal surface through a funnel kept at a certain convenient height. The height of the heap
was measured and then circumference of the base of heap was drawn on a graph sheet with the
help of a pencil. The radius of the circle obtained was measured. The angle of repose is given as,
θ=tan-1 (h/r)
Where, θ= angle of repose
h= height of the heap
r = radius of the base of the heap
Table no. 8: limits of angle repose value
Angle of Repose (Degrees) Type of Flow
<20 Excellent
20-30 Good
30-34 Passable
>40 Very Poor
6.5.5. PARTICLE SIZE DETERMINATION 42, 45, 51:
In order to determine the particle size distributions of the prepared pellets containing
lansoprazole, standard sieve method was used. Mechanical sifter with sieves between apertures
355-2000 μm were used by using all the amount of pellets prepared. The fraction collected on
each of the sieves was calculated by the percentage value.
6.5.6. ASSAY STUDY 71:
Chromatographic condition
Column: 4.6mm ID x 25cm long. Packaged with C18 with particle size 5µ.
Flow Rate: 1.0 ml/min.
Wave length: 285 nm
Buffer PH: Dissolved 6.8 gm of potassium dihydrogen orthophosphate in 1000ml water.
Adjusted PH 7.4 with 0.1 M sodium hydroxide.
Mobile Phase: Prepared a suitable quantity of a filtered and degassed mixture of 65 volumes of
phosphate buffer PH 7.4 and 35 volumes of acetonitrile.
Standard preparation:
Lansoprazole pellets (10 mg.) was weighed accurately and transferred into a 100 ml
volumetric flask. 40 ml of 0.1 M Sodium hydroxide was added and sonicated to dissolve. Made
volume up to the mark with 0.1 M sodium hydroxide and mixed. Transferred 5 ml of the solution
to 50 ml with mobile phase and mixed.
Sample Preparation:
Took around 5 gms of pellets into a mortar and pestle and grinded the pellets into a
uniform fine powder. Weighed accurately about a quantity equivalent to 30mg of Lansoprazole
into a dry 100 ml volumetric flask, added about 50 ml of 0.1 M NaOH and sonicated to dissolve.
Made volume up to the mark with 0.1 M sodium hydroxide and mixed. Transferred 20 to 30 ml
of solution into dry stopper test-tube, centrifuge at 5000 rpm for 5 minutes. Further, diluted 5 ml
of the supernatant solution to 50 ml with mobile phase.
Procedure:
Injected sample preparation in duplicate into the chromatograph and recorded the
chromatograms. Measured the response for the major peaks. Calculated the quantity in % w/w of
Lansoprazole by using below formula.
AT          WS              5               100 50
Calculation: -------- X --------- X -------- X --------- X -------- X P
AS          100              50             WT           5
AT= Average peak area of sample preparation
AS = Average peak area of standard replicate injection
WS = Weight of working standard in mg
WT = Weight of sample taken in mg
P     = Purity of working standard
6.5.7. GASTRIC ACID RESISTANT TEST 41, 55:
Acid resistance test is a significant index of drug dissolution performance of enteric
coated formulations. Model fraction of coated pellets was subjected for acid resistance test in
USP dissolution test apparatus –II (SR-8, Hanson Research, and Chatsworth, USA). Weighed
amount of pellets were placed in the vessel and test was carried out in 0.1N HCl for 1hr at 75
rpm. Lansoprazole released at 1hr in 0.1 N HCl was estimated as per method specified in USP.
Minimal amount of drug release in this test is indicative of gastric acid resistance.
6.5.8. INVITRO DISSOLUTION STUDY 40, 41, 55, 56:
Method:
Dissolution studies were carried out for all the formulations, employing USP-II paddle
method 500 ml of 0.1 N HCL for first 1 hr and 900 ml of phosphate buffer pH-6.8 for next 1 hr
were used as the dissolution medium. The medium was allowed to equilibrate to temp of 37°c +
0.5°c. Pellets were placed in the vessel and the vessel was covered and operated for 1 hr in 0.1 N
HCL at 75 rpm and next 1 hr pH-6.8 phosphate buffer at 100 rpm. At definite time intervals of 5
ml of the aliquot of sample was withdrawn periodically and the volume replaced with equivalent
amount of the fresh dissolution medium. The samples were analyzed spectrophotometrically at
281 nm using UV-spectrophotometer.
Preparation 0f 0.1 N HCL:
Transferred 8.5 ml of HCL into a suitable container containing water, dilute to 10,000 ml
with purified water and mixed.
Dissolution Parameters
Medium                                         : 0.1 N HCL
Volume                                          : 500 ml
Apparatus                                      : USP type II (paddle)
Speed                                             : 75 RPM
Temperature                                  : 37.0˚c ± 0.5˚c
Sampling point                              : 15, 30, 45 and 60 min.
Preparation of buffer:
Weighed and transferred 1.41 grams of disodium hydrogen phosphate anhydrous into a
beaker containing 1000 ml of water. Filtered through 0.45μ membrane filter.
Dissolution Parameters:
Medium                                        : PH 6.8 phosphate buffer
Volume : 900ml
Apparatus                                      : USP type II (paddle)
Speed                                             : 100 RPM
Temperature                                  : 37.0˚c± 0.5˚c
Sampling points : 75, 90,105 and 120 min
6.5.9. SCANNING ELECTRON MICROSCOPY 45, 46:
Photo micro graphs were taken with a scanning electron microscope for visualization of
spherocity of the pellets. Pellets were coated with platinum by means of a sputter coater to assure
conductivity.
6.5.10. COMPARISON OF DISSOLUTION PROFILE OF OPTIMIZED FORMULATION
WITH MARKETED FORMULATION 40, 41, 55, 56:
Invitro study of marketed formulation was carried out according to the procedure given in
section 6.5.8. Graph of cumulative percentage drug release Vs time (hour) for both the optimized
formulation and marketed product was plotted.
6.5.11. ACCELERATED STABILITY STUDY 40, 41, 55:
The purpose of stability testing is to provide evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental
factors such as temperature, humidity and light and to establish a retesting for the drug substance
or a shelf-life for the drug product and recommended storage conditions.
Stability testing of drug products begins as a part of drug discovery and ends with the
demise of the compound or commercial product.ICH specifies the guidelines for stability testing
of new drug products, as a technical requirement for the registration of pharmaceuticals for
human use.
The ICH Guidelines have established that accelerated stability testing should be done at
400C/75%RH for 3 months.
Stability study was carried out for the optimized formulation. Tablets of optimized
formulation were packed in strip and kept in stability chamber for 3 months on above mention
temperature. Samples were analyzed at 1, 2, 3 months for invitro dissolution study.
ICH guidelines for stability study
Table no.9: ICH guidelines
Study Storage condition Time period
Long term*
25°c±2°c/60% RH±5% RH
or
30°c±2°c/65% RH±5% RH
12 month
Intermediate** 30°c±2°c/65% RH±5% RH 6 month
Accelerated 40°c±2°c/75% RH±5% RH 6 month
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7. RESULTS AND DISCUSSION
7.1. PREFORMULATION STUDIES:
7.1.1. SOLUBILITY:
Sparingly soluble in ethanol and insoluble in water and hexane
7.1.2. MELTING POINT:
The Melting point of lansoprazole was found to be 178-182 oC
7.1.3. BULK AND TAPPED DENSITY
Table no.18: Bulk density and tapped density of lansoprazole
Material Bulk Density (gm/ml) Tapped density  (gm/ml)
LANSOPRAZOLE 0.90 1.10
7.1.4. LOSS ON DRYING:
LOD of lansoprazole was found to be 0.39% w/w (not more than2 % w/w)
7.1.5. COMPATIBILITY STUDIES:
FTIR spectrum of lansoprasole and physical mixture of lansoprasole and excipient were
obtained according to procedure given in section 6.3.6. and results given in fig. no.19 to fig. no.
22 and characteristics peak values given in table no.10.
Figure no.19: FTIR Spectra of lansoprazole
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Figure no.20: FTIR Spectra of lansoprazole with HMPC E5
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Figure no.21: FTIR Spectra of lansoprazole with Eudragit L30 D55
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Figure no.22: FTIR Spectra of lansoprazole pellets
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The IR Spectroscopy study showed following characteristic peaks of functional groups in
lansoprazole.
Table No.10: IR Interpretation of Lansoprazole Drug
The Lansoprazole showed characteristic peaks at 1306, 1275 (N-H), 1600-1430 (N=N,
C=C), 1400-1000 (C-F) and pyridine ring peak at 1600-1430 cm-1. The FTIR study showed that
selected polymers were compatible with drug as all characteristic peaks of Lansoprazole were
present in physical mixture of drug and polymer. Hence further formulations were prepared and
evaluated for optimization of the formulation.
From the IR spectroscopy it was clear that the Lansoprazole was compatible with the
polymer used Eudragit L30 D55 and HPMC E- 5.
Table No.11: Drug - Excipient Compatibility Studies
Sr.
no.
Functional Groups Theoretical value in cm-1 Observed valuein cm-1
1 N-H 1306,1275 1281.47
2 N=N & C=C 1600-1430 1455.99
3 C-F 1400-1000 1401.03
4 Pyridine Ring 1600-1430 1579.47
Sr. No. Name of ingredient Category Remarks
1 HPMC E- 5 Film former Compatible
2 Eudragit L30 D55 Enteric coating agent Compatible
7.1.6. CALIBRATION CURVE OF LANSOPRAZOLE:
Calibration curve of lansoprazole was determined by plotting absorbance/concentration
(mcg/ml) at 281nm, the results obtained were given in table no.12 and fig. no.16.
Table No.12: Standard Graph Readings (visible spectra)
Concentration (µg/ml) Absorbance(nm)
0 0.0
10 0.220
20 0.420
30 0.610
40 0.790
50 0.970
The linear regression analysis was done on absorbance data points. A straight line
generated to facilitate the calculation of amount of drug, the equation is as follows:
Y = mx + c
Figure no.14: Standard plot of Lansoprazole
The above graph showed the standard curve of the Lansoprazole and from it correlation
coefficient value was calculated as 0.998.
The above graph showed the linearity in curve and therefore it revealed that it follows the
beers law.
7.2. FORMULATION OF LANSOPRASOLE PELLETS:
According to the formula and procedure given the section 6.4, pellets of all batches were
formulated.
7.3. EVALUATION OF FORMULATED LANSOPRAZOLE PELLETS:
Evaluation of formulated lansoprasole pellets were carried out according to procedure
given section 6.5.
7.3.1. FRIABILITY TEST:
Results for friability test were given in the table no.13 and fig. no.23.
Table No. 13: percent friability of formulations F1 to F9
SR.NO. FORMULATION FRIABILITY%
1 F1 0.65±0.01
2 F2 0.72±0.03
3 F3 0.55±0.02
4 F4 0.62±0.07
5 F5 0.73±0.03
6 F6 0.58±0.01
7 F7 0.46±0.02
8 F8 0.62±0.03
9 F9 0.77±0.05
All values represent mean ± standard deviation (SD) n=3.
Figure no.23: percent friability of various formsulations
Above graph showed the percent friability of all formulations and it was observed that all
the prepared pellets showed that percent friability value less than 1%, therefore the results were
within the range.
7.3.2. BULK AND TAPPED DENSITY
Table no.14: bulk and tapped density of formulation of F1 toF9
Formulation
Code
Bulk Density
(g/ml)
Tapped Density
(g/ml)
Hausner Ratio Carr’s Index
F1 0.923±0.02 0.989±0.03 1.07±0.01 5.47±0.03
F2 0.937±0.03 1.0048±0.06 1.07±0.05 5.71±0.06
F3 0.921±0.02 0.988±0.02 1.07±0.04 4.38±0.07
F4 0.934±0.02 0.991±0.04 1.06v0.02 4.96±0.08
F5 0.915±0.3 0.959±0.05 1.04±0.02 5.21±0.04
F6 0.952±0.04 0.999±0.02 1.04±0.06 5.47±0.04
F7 0.947±0.01 1.028±0.04 1.08±0.07 5.39±0.06
F8 0.928±0.02 0.972±0.06 1.04±0.01 5.11±0.03
F9 0.938±0.04 0.987±0.4 1.05±0.04 4.96±008
All values represent mean ± standard deviation (SD) n=3.
The result showed in table no.14 given the the bulk and tapped density, Hausner ratio and
Carr’s Index for all formulation and all values were found within limit, therefore it revealed that
the pellets of all formulations has good flow property.
7.3.3. ANGLE OF REPOSE:
Results for angle of repose given in table no.15.
Table No.15: angle of repose of formulations
Formulation
code F 1 F 2 F 3 F 4 F 5 F 6 F 7 F8 F 9
Angle of
repose(degree) 27.32 26.56 28.12 28.54 29.21 27.76 29.23 27.45 28.23
All values represent mean (n) =3.
The angle of repose of formulations from F1 to F9 found between 26.56 to 29.23, so
angle of repose of all formulation were below 30, therefore it was indicates that pellets were
having good flow property.
7.3.4. PARTICLE SIZE DETERMINATION:
Results for particle size determination were given in the table no. 16.
Table No.16: angle of repose of formulations
Formulation
code
F 1 F 2 F 3 F 4 F 5 F 6 F 7 F8 F 9
Particle size
(µm)
1165.47 1128.56 1194.34 1034.23 1134.51 1098.57 1057.25 1147.78 1196.45
All values represent mean (n) =3.
From above results it was observed that the average particle sizes of the pellets were
nearly 1200 μm for all 9 formulations.
7.3.5. ASSAY STUDIES
Results for assay studies were given in table no.17 and fig. no.24 to 33.
Table No.17: Assay Observation
S.NO FORMULATIONS %ASSAY
1 F1 96.70±0.02
2 F2 98.40±0.04
3 F3 89.60±0.03
4 F4 91.88±0.06
5 F5 94.83±0.07
6 F6 93.50±0.0.2
7 F7 94.88±0.03
8 F8 95.49±0.07
9 F9 98.50±0.04
All values represent mean ± standard deviation (SD) n=3.
Figure No.24: percent assay of various formulations
Above graph showed the percent drug content in each formulations and it was observed
that the all formulations content the drug within the limit (not less than 89% and not more than
109%)
Figure no.25: Chromatogram of Lansoprazole Pure Drug
HPLC
peak showing a retention time of 2.53
Figure no. 26: Chromatogram of Lansoprazole (F1 batch)
HPLC peak showing a retention time of 2.51corresponding to lansoprazole at 288nm
Figure no. 26: Chromatogram of Lansoprazole (F2 batch)
HPLC peak showing a retention time of 2.54 corresponding to lansoprazole at 288nm
Figure no. 27: Chromatogram of Lansoprazole (F3 batch)
HPLC peak showing a retention time of 2.53 corresponding to lansoprazole at 288nm
Figure no. 28: Chromatogram of Lansoprazole (F4 batch)
HPLC peak showing a retention time of 2.56 corresponding to lansoprazole at 288nm
Figure no. 29: Chromatogram of Lansoprazole (F5 batch)
HPLC peak showing a retention time of 2.55 corresponding to lansoprazole at 288nm
Figure no. 30: Chromatogram of Lansoprazole (F6 batch)
HPLC peak showing a retention time of 2.55 corresponding to lansoprazole at 288nm
Figure no. 31: Chromatogram of Lansoprazole (F7 batch)
HPLC peak showing a retention time of 2.57 corresponding to lansoprazole at 288nm
Figure no. 32: Chromatogram of Lansoprazole (F8 batch)
HPLC peak showing a retention time of 2.52 corresponding to lansoprazole at 288nm
Figure no. 33: Chromatogram of Lansoprazole (F9 batch)
HPLC peak showing a retention time of 2.54 corresponding to lansoprazole at 288nm
7.3.6. GASTRIC ACID RESISTANCE TEST:
Results for the acid resistant test were given in table no.18 and fig. no.34.
Table No. 18: percent gastric resistant of formulation F1 to F9
FORMULATION % ACID RESISTANCE
F1 89.68±0.05
F2 91.06±0.03
F3 95.87±0.07
F4 87.97±0.01
F5 92.33±0.04
F6 89.49±0.03
F7 90.56±0.02
F8 96.87±0.06
F9 95.78±0.02
All values represent mean ± standard deviation (SD) n=3.
Figure no.34: Acid resistance dissolution data
The above graph showed the percent acid resistant of all formulations and it was
observed that the all formulations have better acid resistant.
7.3.7. INVITRO DISSOLUTION STUDIES:.
Results for invitro dissolution studies were given the table no.19 and graph for
formulations F1 to F3, F4 to F6 and F7 to F9 in 0.1N HCL were showed in fig. no. 35, 36 and 37
respectively and graph for formulation F1 to F3, F4 to F6 and F7 to F9 in phosphate buffer pH
6.8 were showed in fig. no. 38, 39 and 40 respectively.
Table No.19: Cumulative percentage of lansoprazole release in 0.1N HCL and phosphate
Buffer pH 6.8
All values represent mean (n) =3.
Cumulative Percent drug release in 0.1 N HCL
TIME
(MIN)
F1 F2 F3 F4 F5 F6 F7 F8 F9
0 0 0 0 0 0 0 0 0 0
15 0.67 0.65 0.61 0.70 0.73 0.59 0.56 0.52 0.49
30 0.72 0.69 0.65 0.72 0.66 0.62 0.60 0.58 0.57
45 0.85 0.83 0.90 0.80 0.77 0.74 0.71 0.68 0.64
60 0.91 0.87 0.85 0.83 0.96 0.81 0.79 0.76 0.71
Cumulative Percent drug release in phosphate buffer pH 6.8
75 55.13 58.01 60.22 62.11 70.15 65.22 67.33 69.45 71.25
90 67.04 62.11 65.09 67.41 69.05 72.18 75.13 77.03 79.10
105 65.34 75.65 67.45 71.07 73.19 76.24 79.06 82.18 85..0
9
120 67.57 72.56 75.34 79.13 82.67 86.56 90.20 94.15 97.87
Figure no.35: Cumulative Percentage of Release of Lansoprazole in 0.1N HCL
Figure no.36: Cumulative Percentage of Release of Lansoprazole in 0.1N HCL
Figure no.37: Cumulative Percentage of Release of Lansoprazole in 0.1N HCL
From the graphs it was observed that the formulation F9 had better resistant to 0.1N HCL
as compared to other formulations. And this is because formulation F9 contains high
concentration of sugar sphere and HPMC K5 and low concentration of eudragit L30 D 55. As
sugar sphere used in high concentration it giving a thin layer of drug on each pellets and  HPMC
K5 used in high concentration forming a thick layer between drug and enteric polymer, so it
prevent the interaction between the drug and enteric polymer. Therefore formulation F9 showed
the better resistant to 0.1N HCL.
Figure no.38: Cumulative Percentage of drug Release of Lansoprazole in phosphate buffer
pH 6.8
Figure no.39: Cumulative Percentage of drug Release of Lansoprazole in phosphate buffer
pH 6.8
Figure no.40: Cumulative Percentage of drug Release of Lansoprazole in phosphate buffer
pH 6.8
From the results it was observed that the formulation F9 has better cumulative percent
drug release as compared to other formulations. Because it may be in formulation F9 Eudragit
L30 D55 was used in low concentration, therefore the drug release from pellets occurs fastly in
phosphate buffer pH 6.8. While keeping in 6.8 pH buffer, 71.25 cumulative percent drug release
occur at 75 minutes, After 120 minutes 97.87 cumulative percent drug release was attained,
when compared to other formulation F9 showed better release, so F9 was selected as optimized
formulation.
7.3.8. SCANNING ELECTRON MICROSCOPY:
The scanning electron microscopy of formulation F9 showed that prepared pellets have
good coating and film former and it is helpful in controlling the release of drug in acidic
medium.
Figure no.41: SEM of Formulation F9:
7.3.9. COMPARISON OF INVITRO DISSOLUTION DATA OF OPTIMIZED
FORMULATION WITH MARKETED FORMULATION:
Results for comparison of invitro dissolution data of optimized formulation with
marketed formulation were given table no.20 and fig. no.42 and fig. no.43.
Table No.20: comparison of cumulative % drug release in 0.1N HCL and phosphate buffer
pH 6.8 of optimized Formulation with marketed product.
1) IN 0.1 N HCL
TIME IN MIN. F9 MARKETED
FORMULATION
0 0 0
15 0.49 0.51
30 0.57 0.59
45 0.64 0.65
60 0.71 0.73
2) IN PHOSPHATE BUFFER 6.8
75 71.25 69.43
90 79.10 78.05
105 85..09 83.54
120 97.87 95.71
All values represent mean (n) =3.
Figure no.42:  Comparison of Dissolution Profile of Optimized Formulation with
Marketed Formulation in 0.1 N HCL
Optimized formulation (F9) was compared with the marketed product. The invitro
values have been obtained in limits compared to the marketed product. By these values
concluded that optimized formulation has better resistance to 0.1N HCL compared to the
marketed product.
Figure no.43: Comparison of Dissolution Profile of Optimized Formulation with Marketed
Formulation
Optimized formulation (F9) was compared with the marketed product. The dissolution
values have been obtained and showed the better release of drug as compared to the marketed
product in phosphate buffer pH 6.8.
7.3.10. Accelerated stability study
Stability profile of Formulation F9
Table No. 21: Dissolution data of stability
1) IN 0.1 N HCL
S.No. Time(min) Cumulative % drug release
Initial 1 month 2 months 3 months
1 0 0 0 0 0
2 15 0.49 0.46 0.43 0.39
3 30 0.57 0.55 0.53 0.49
4 45 0.64 0.62 0.55 0.51
5 60 0.71 0.69 0.63 0.54
2) IN PHOSPHATE BUFFER 6.8
6 75 68.25 68.25 68.25 68.25
7 90 77.10 77.10 77.10 77.10
8 105 84.09 83.96 83.70 83.65
9 120 97.76 97.73 97.65 97.55
All values represent mean ± standard deviation (SD) n=3.
Figure no.44: Comparison of Dissolution Data of Stability IN 0.1 N HCL
Figure no.45: Comparison of Dissolution Data of Stability IN 0.1 N HCL
After comparison of dissolution data of stability at 0, 1, 2, 3 months there was no changes
observed, and clearly showing that the formulated product was stable.
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8. SUMMARY AND CONCLUSION
The study was undertaken with an aim to develop an optimized formulation of
Lansoprazole Enteric Coated Pellets drug delivery system by using Eudragit L-30D-55, HPMC
K5 as retarding agents. The active pharmaceutical ingredient, Lansoprazole was selected and
formulated as Enteric Coated Pellets comparable to the innovators product.
In the present work, preformulation studies were conducted to know the drug excipients
compatibility by using FTIR spectroscopy. Based on the results, suitable excipients were selected
for formulation development. FTIR spectra revealed that there was no significant interaction
between drug and polymer.
Pellets were prepared by using Suspension layered method. Finished products were
evaluated for friability test, assay, and In-vitro release studies performed for 1hr in acidic media
at 0.1N HCL, after that 1 hr in 6.8 pH Phosphate buffer.
From the evaluation it was concluded that percent friability and percent assay for all
formulations from F1 to F9 were found within the limit. Invitro dissolution study showed that
Formulation F9 having the better resistance in 0.1 N HCL and good release in phosphate buffer
pH 6.8.
From the above results and discussion it might be concluded that the formulation F9 of
enteric coated pellets of Lansoprazole was found to be stable in acidic medium and shows better
drug release in basic medium. Therefore it was an ideal and optimized formulation of enteric
coated pellets.
Then the optimized formulation F9 was compared with marketed product by an invitro
study, it shows that the formulation F9 was good as compared with marketed one.
The stability study was carried out for formulation F9 at 1, 2, 3 month for invitro
dissolution study and from this it was observed that there were no changes and clearly showing
that the optimized formulation F9 was stable.
In future, this work extends for in-vivo study.
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